EVALUATION OF EOSINOPHILIC ESOPHAGITIS

Info

Publication number: 20090269774
Type: Application
Filed: Jun 26, 2009
Publication Date: Oct 29, 2009
Applicant: CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER (Cincinnati, OH)
Inventors: Marc E. Rothenberg (Cincinnati, OH), Carine Blanchard (Cincinnati, OH)
Application Number: 12/492,456

Abstract

A method to evaluate eosinophilic esophagitis based on information in an eosinophilic esophagitis transcriptome.

Description

Description

RELATED APPLICATION

This application is a Continuation in Part of U.S. application Ser. No. 11/721,127 filed Jun. 7, 2007, which claims priority from PCT/US2005/044456 filed Dec. 7, 2005, which claims priority from U.S. application Ser. No. 60/633,909 filed Dec. 7, 2004, each of which is expressly incorporated by reference herein in its entirety.

The U.S. Government has a paid-up license in this invention and the right in limited circumstances to require the patent owner to license others on reasonable terms as provided for by the terms of Grant No. 2R01AI045898-05 awarded by the National Institutes of Health.

FIELD OF THE INVENTION

The invention is directed generally to evaluating and mitigating eosinophilic esophagitis.

BACKGROUND

Patients with eosinophilic esophagitis may have symptoms that include abdominal pain, difficulty swallowing, vomiting, failure to thrive and weight loss. In addition, allergy, particularly food allergy, is an associated finding in most patients, and many have concomitant asthma or other chronic respiratory disease. Diagnosis requires endoscopy, and diseased tissue shows characteristic punctate white surface dots associated with erythema, loss of vascular pattern, ulcers, or ringed trachea-like appearance.

Patients with eosinophilic esophagitis typically have elevated levels of eosinophils in esophageal tissue and peripheral blood. Eosinophils are one type of granulocytic leukocyte (white blood cell) or granulocyte that normally appears in the peripheral blood at a concentration of about 1-3% of total leukocytes. Their presence in tissues is normally primarily restricted to the gastrointestinal mucosa, i.e. the stomach and intestines. Eosinophil accumulation in the peripheral blood and tissues is a hallmark feature of an allergic response, and may cause potent pro-inflammatory effects or tissue remodeling. Because eosinophilic esophagitis is marked by infiltration of eosinophils, this condition may be linked to allergen exposure. Eosinophil accumulation occurs in other allergic diseases such as allergic rhinitis, asthma, and eczema as well as parasitic infections, certain types of malignancies, chronic inflammatory disorders such as inflammatory bowel disease, specific syndromes such as eosinophilic gastroenteritis, eosinophilic colitis, eosinophilic cellulitis, eosinophilic fascitis, and systemic diseases such as Churg Strauss syndrome, eosinophilic pneumonia, and the idiopathic hypereosinophilic syndrome.

Numerous mediators have been identified as eosinophil chemoattractants. These include diverse molecules such as lipid mediators (platelet activating factor (PAF), leukotrienes) and chemokines such as the eotaxin subfamily of chemokines. Chemokines are small secreted proteins produced by tissue cells and leukocytes that regulate leukocyte homing during homeostatic and inflammatory states. Two main subfamilies (CXC and CC chemokines) are distinguished depending upon the arrangement of the first two cysteine amino acids, either separated by one amino acid (CXC), or adjacent (CC).

Due to the increasing incidence of eosinophilic esophagitis, methods to mitigate eosinophilic esophagitis would be beneficial. In addition, because eosinophilic esophagitis is often confused with other disorders such as gastroesophageal reflux disease (GERD), but does not typically respond to anti-GERD therapy, it is important to develop diagnostic features that distinguish between eosinophilic esophagitis and GERD. Diagnosis currently requires endoscopy with subsequent biopsy and analysis of the excised tissue by a pathologist based on manual microscopic analysis, so that less invasive methods of diagnosing eosinophilic esophagitis would also be beneficial.

SUMMARY OF THE INVENTION

The terms normal individuals, individuals without eosinophilic esophagitis (EE), control group or controls, patients without EE, and normal patients are used synonymously. The terms individuals with EE, treated groups, EE patients, and patients with EE are used synonymously.

One embodiment of the invention is a method of assessing eosinophilic esophagitis (EE) in a patient by comparing the patient's blood concentration of eotaxin-3 to a normal concentration of eotaxin-3, where an increased concentration of eotaxin-3 indicates EE.

Another embodiment of the invention is a diagnostic assay for EE. One embodiment of the assay may include a test strip containing an anti-eotaxin-3 antibody and at least one reagent that indicates binding of the anti-eotaxin-3 antibody to eotaxin-3 present in a supranormal level in a biological sample. Detection may be by visual inspection for a chromogen, fluorogen, colloidal gold agglutination, luminescence, etc.

Another embodiment of the invention is a diagnostic method for EE where eotaxin-3 DNA, eotaxin-3 mRNA, and/or eotaxin-3 protein is present over a normal amount in a patient tissue, as an indicator of EE in the patient.

Another embodiment of the invention is a diagnostic method for EE where a frequency of single nucleotide polymorphisms (SNPs) in the eotaxin-3 gene above normal frequency is an indicator of EE or a marker of disease risk, prognosis, and/or a response to therapy.

Another embodiment of the invention is a method to mitigate EE by providing an inhibitor to eotaxin-3 and/or a receptor, such as CCR3, for binding eotaxin-3 in a cell, such as a mast cell or an eosinophil, under conditions sufficient to inhibit eotaxin-3 binding to the receptor.

Another embodiment of the invention is a gene expression profile for EE comprising SEQ. ID NOS. 1-1620.

Another embodiment of the invention is a method to evaluate EE by gene expression profiles, where evaluation encompasses assessment of disease propensity, of disease severity, of therapy efficacy, of therapy compliance, etc. In one embodiment, EE is evaluated by determining an expression profile of at least one gene in the esophagus of the patient, where the gene is selected from SEQ ID NOS. 1-1620. In one embodiment, EE is evaluated by determining an expression profile of at least one gene in the patient, where the gene is selected from group consisting of SEQ ID NOS. 1-1620. The expression profile of the selected gene(s) is then compared to the expression profile of that same gene in an individual that does not have EE. The patient's propensity for EE is evaluated by determining if the gene in the patient is either over-expressed ≧1.5 times or is under-expressed ≧1.5 times compared to the same gene in the expression profile in the individual without EE. This propensity is evaluated by determining the extent that over-expression or under-expression exceeds 1.5, the identify of the gene over-expressed or under-expressed, and/or the number of genes that are over-expressed or under-expressed. The patient's propensity for EE is higher based on at least one of the farther the over-expression or under-expression is from 1.5, the gene is from SEQ ID NO. 1-42, and/or the greater the number of genes that are over-expressed or under-expressed. In one embodiment the gene is SEQ ID NO.1. In one embodiment, the patient lacks at least one clinical and/or physical symptoms of EE. In one embodiment, the cell is an esophageal cell.

Another embodiment of the invention is a method to evaluate a compound's contribution to the pathophysiology of EE. At least one cell, referred to as the test cell, is exposed to the compound, and an expression profile of at least one gene selected from the group consisting of SEQ ID NOS. 1-1620 in the cell(s) is compared to an expression profile of at least one gene selected from the group consisting of SEQ ID NOS. 1-1620 in a cell of an individual without EE, referred to as the control cell. The contribution of the compound to the pathophysiology of EE is evaluated by determining if the at least one gene in the test cell is either over-expressed ≧1.5 times or is under-expressed ≧1.5 times compared to the same gene in the expression profile of the control cell. The compound's contribution to the pathophysiology of EE is evaluated by determining the extent that over-expression or under-expression exceeds 1.5, the identify of the gene over-expressed or under-expressed, and/or the number of genes that are over-expressed or under-expressed. The compound contributes more to the pathophysiology of EE based on at least one of the farther the over-expression or under-expression is from 1.5, the gene is from SEQ ID NO. 1-42, and/or the greater the number of genes that are over-expressed or under-expressed. In one embodiment, the cell is an esophageal cell. In one embodiment, based on the extent that the compound contributes to EE, therapeutics that antagonize the action of the compound may be used to treat EE.

Another embodiment of the invention is a method to evaluate an individual's response to therapy for EE. An expression profile of at least one gene selected from the group consisting of SEQ ID NOS. 1-1620 in an esophagus of an individual exposed to therapy is compared to an expression profile of the same gene(s) from an individual without EE. The individual's response to therapy for EE is evaluated by determining if the at least one gene is either over-expressed ≧1.5 times or is under-expressed ≧1.5 times compared to the same gene in the expression profile from the individual without EE. The individual's response to therapy for EE is evaluated based on the extent that over-expression or under-expression exceeds 1.5, the identify of the gene over-expressed or under-expressed, and/or the number of genes that are over-expressed or under-expressed. The individual is less responsive to therapy for EE based on at least one of the farther the over-expression or under-expression is from 1.5, the gene is from SEQ ID NO. 1-42, and/or the greater the number of genes that are expressed or under-expressed.

Another embodiment of the invention is a method to evaluate an individual's compliance with therapy for EE. An expression profile of at least one gene selected from the group consisting of SEQ ID NOS. 1-1620 in an esophagus of an individual prescribed therapy for EE is compared to an expression profile of the same gene(s) from an individual without EE. The individual's compliance with therapy is evaluated by determining if the at least one gene is either over-expressed ≧1.5 times or is under-expressed ≧1.5 times compared to the same gene in the expression profile from the individual without EE. The individual's compliance with therapy is determined based on the extent that over-expression or under-expression exceeds 1.5, the identify of the gene over-expressed or under-expressed, and/or the number of genes that are over-expressed or under-expressed. The individual is less compliant with therapy for EE based on at least one of the father the over-expression or under-expression is from 1.5, the gene is from SEQ ID NO. 1-42, and/or the greater the number of genes that are over-expressed or under-expressed. That is, the gene expression is more like an individual with EE than a normal EE without EE.

Another embodiment of the invention is a method to evaluate whether an individual had EE prior to a current assessment. An expression profile of at least one gene selected from the group consisting of SEQ ID NOS. 6, 35, 43, 61, 129, 1358, 1441, 1515, 1538, 1584, 1615, 1618, and 1620 in an esophagus of an individual is compared to the expression profile of the same gene(s) from an individual without EE. The individual's prior EE is evaluated by determining if the at least one gene is either over-expressed ≧1.5 times or is under-expressed ≧1.5 times compared to the same gene in the expression profile from the individual without EE. The likelihood of the individual having EE prior to the current assessment is determined based on the extent that over-expression or under-expression exceeds 1.5, the identity of the gene over-expressed or under-expressed, and/or the number of genes that are over-expressed or under-expressed. The individual is more likely to have had prior EE based on at least one of the farther the over-expression or under-expression is from 1.5, and/or the greater the number of genes that are over-expressed or under-expressed. In one embodiment, the individual does not have active EE when the method is performed.

These and other advantages will be apparent in light of the following figures and detailed description.

BRIEF DESCRIPTION OF THE DRAWINGS

The patent or application file contains at least one drawing executed in color. Copies of this patent or patent application publication with color drawing(s) will be provided by the Office upon request and payment of the necessary fee.

FIG. 1 shows DNA microarray data of eotaxin-3 mRNA levels in esophageal tissue of normal patients and patients with eosinophilic esophagitis (EE).

FIG. 2 shows data from quantitative polymerase chain reaction analysis showing normalized eotaxin-3 mRNA levels in normal patients, patients with gastroesophageal reflux disease (GERD), and patients with EE.

FIG. 3 shows esophageal eosinophil concentration in control and allergen-induced wild-type mice, and allergen-induced mice lacking the gene encoding the CCR3 receptor.

FIG. 4 shows plasma concentrations of eotaxin-3 in normal patients and patients with EE.

FIG. 5 shows hierarchical cluster analysis of transcripts expressed in normal (NL), reflux (RE), and EE esophageal biopsies.

FIG. 6 shows fluticasone propionate treatment-resistant genes within the EE transcriptome.

DETAILED DESCRIPTION

Methods of diagnosing, assessing, and mitigating eosinophilic esophagitis (EE) by modulating levels and activity of eotaxin-3 and by evaluating gene expression profiles are disclosed.

Eotaxin-3 is a CC chemokine with selective activity on eosinophils. For example, eotaxin-3 recruits and directs eosinophils to sites in the body, such as the esophagus, via chemoattraction. Additional chemokines have been identified in the genome that encode for CC chemokines with eosinophil-selective chemoattractant activity, and have been designated eotaxin-1 and eotaxin-2.

The activity of eotaxin-3 is mediated by the selective expression of an eotaxin receptor, CCR3, on eosinophils. CCR3 is a promiscuous receptor; it interacts with multiple ligands including macrophage chemoattractant proteins (MCP)-2, -3, and -4, RANTES (regulated upon activation normal T-cell expressed and secreted), and HCC-2 (MIP-5, leukotactin). The only ligands that signal exclusively through this receptor, however, are eotaxins-1, -2, and -3, accounting for the cellular selectivity of the eotaxins.

Esophageal tissue obtained from patients previously diagnosed with EE was analyzed. Diagnosis was based on analysis of excised tissue from endoscopic biopsy. Tissues from patients with EE, as well as patients not having EE (controls) were subjected to genome-wide microarray transcript profiling (Affymetrix GeneChip). All work was performed at the Core facility at Children's Hospital Medical Center (Cincinnati Ohio).

Briefly, RNA quality was first assessed using the Agilent bioanaiyzer (Agilent Technologies, Palo Alto Calif.). Only mRNA having a ratio of 28S/18S between 1.3 and 2 were subsequently used. RNA was converted to cDNA with Superscript choice for cDNA synthesis (Invitrogen, Carlsbad Calif.) and subsequently converted to biotinylated cRNA with Enzo High Yield RNA Transcript labeling kit (Enzo Diagnostics, Farmingdale N.Y.). After hybridization to the GeneChip (Affymetrix, Santa Clara Calif.), the chips were automatically washed and stained with streptavidin-phycoerythrin using a fluidics system. The chips were scanned with a Hewlett Packard GeneArray Scanner. Over 30,000 unique genes were screened.

Levels of gene transcripts were determined from data image files, using algorithms in the Microarray Analysis Suite software (Affymetrix). Levels from chip to chip were compared by global scaling. Each gene was typically represented by a probe set of 16 to 20 probe pairs. Each probe pair consisted of a perfect match oligonucleotide and a mismatch oligonucleotide that contained a one base mismatch at a central position. Two measures of gene expression were used, absolute call and average difference. Absolute call is a qualitative measure in which each gene is assigned a call of present, marginal or absent, based on the hybridization of the RNA to the probe set. Average difference is a quantitative measure of the level of gene expression, calculated by taking the difference between mismatch and perfect match of every probe pair and averaging the differences over the entire probe set. Data were normalized and an EE transcriptome gene list was created with results having p<0.01 (Welch t-test with or without false rate discovery) and ≧1.5-fold change.

FIG. 1 shows the normalized relative average difference of the gene encoding eotaxin-3 from normal patients and patients with EE. The microarray analysis identified eotaxin-3 as the top gene induced, indicating a role in EE. Eotaxin-1 and eotaxin-2 mRNA levels were not significantly increased in EE patients.

Quantitative polymerase chain reaction (PCR) using LightCycler technology (Roche Diagnostics Corp. Indianapolis Ind.) which involves a competitive amplification of cDNA prepared from esophageal RNA, known to one skilled in the art, was further utilized to validate the microarray analysis results. Levels of eotaxin-3 mRNA from normal patients, patients with gastroesophageal reflux disease (GERD), and patients with EE were compared. As shown in FIG. 2, eotaxin-3 mRNA was induced nearly 100-fold in patients with EE when normalized to a housekeeping gene GAPDH. Patients with GERD showed only slightly increased levels compared to normal patients. Levels of the other two eotaxin mRNA species (eotaxin-1 and eotaxin-2) were not increased in patient esophageal samples (data not shown), validating the specific role of eotaxin-3.

A murine model of EE was evaluated to determine the role of the eotaxin-3 receptor, CCR3. The model is disclosed in Mishra et al., J. Clin. Invest. (2001) 107, 83, which is expressly incorporated by reference herein in its entirety. Because EE is marked by infiltration of eosinophils, this condition may be linked to exposure to allergens. In support of this, animals models of EE were induced by allergen exposure to the respiratory tract. In brief, mice were exposed to repeated doses of intranasal Aspergillus fumigatus antigen (three doses a week) for three weeks. Subsequently, the mice were euthanized 18 hours after the last dose of allergen or saline control, and the esophagus was analyzed for the occurrence of EE.

Specifically, asthma was experimentally induced in wild-type and CCR3 knockout (KO) mice (a gift of Drs. Craig Gerard and Allison Humbles at Harvard Medical School) using Aspergillus fumigatus (ASP) as an allergen. Wild-type control mice received saline. The concentration of eosinophils was determined in the esophagus of allergen-induced wild-type mice (ASP wt), control wild-type mice (saline wt), and allergen-induced mice lacking the gene encoding CCR3 (ASP CCR3KO). The results are shown in FIG. 3.

The concentration of eosinophils in allergen-induced wild-type mice (ASP wt) was about 75 eosinophils per mm². The concentration of eosinophils in allergen-induced CCR3KO mice (ASP CCR3KO) was about 4 eosinophils per mm², similar to the eosinophil concentration in control wild-type mice (saline wt). The decreased concentration of eosinophils in allergen-induced CCR3KO mice compared to allergen-induced wild-type mice was statistically significant (p=0.04; Student's T-test). EE-related symptoms and/or pathology may be mitigated by mediating eosinophil chemotactic events using techniques such as those disclosed in U.S. Pat. No. 6,780,973, which is expressly incorporated by reference herein in its entirety. One example is a recombinant polypeptide capable of mediating eosinophil chemotactic events where the polypeptide includes a domain having a sequence which has at least 70% identity to full length murine eotaxin cDNA, full length guinea pig eotaxin cDNA, and/or human eotaxin DNA. Another example is reducing eotaxin activity using an antagonist such as an antieotaxin-3 antibody or eotaxin-1, -2, or -3 fragment, a purified antibody which binds specifically to a murine or human eotaxin-3 protein indicating an intact monoclonal or polyclonal antibody, an immunologically active antibody fragment, or a genetically engineered fragment. The antagonist may be an eotaxin-1, -2, or -3 polypeptide having a deletion of 1-10 N-terminal amino acids, or having an addition of 3-10 amino acids on the amino terminus.

The concentration of eotaxin-3 protein in plasma was elevated in patients with EE, compared to normal controls. Concentrations were determined using a commercially purchased sandwich ELISA kit (R&D Quantikine CCL-26 kit, R&D Systems Inc., Minneapolis Minn.). In blood anticoagulated with heparin, eotaxin-3 concentrations in plasma of normal patients were 29.43 pg/ml±15.4 pg/ml (n=6), and eotaxin-3 concentration in patients with eosinophilic esophagitis were 52.97 pg/ml±12 pg/ml (n=3) (p=0.055). In blood anticoagulated with ethylenediamine tetraacetic acid (EDTA), eotaxin-3 concentrations in plasma of normal patients were 8.3 pg/ml±7 pg/ml (n=15), and eotaxin-3 concentration in patients with eosinophilic esophagitis were 18.19 pg/ml±7 (n=4) (p=0.044). These data are shown in FIG. 4. Therefore, the blood concentration of eotaxin-3 in an individual may be compared to a normal level as a relatively non-invasive or minimally invasive indication of eosinophilic esophagitis. In one embodiment, a plasma concentration of eotaxin-3 of about 52.97 pg/ml±12 pg/ml in blood anticoagulated with heparin is indicative of EE. In another embodiment, a plasma concentration of eotaxin-3 of about 18.19 pg/ml±7 pg/ml in blood anticoagulated with EDTA is indicative of EE. These blood concentrations of eotaxin-3 may serve as a diagnostic marker, for which a less invasive diagnostic test for EE may be used, as further discussed below, to replace or serve as a preliminary indicator or whether a more invasive test, e.g. endoscopic biopsy, is warranted. The level of eotaxin-3 may also serve to determine if a specific therapy is mitigating EE, and thus may be used to monitor therapy. Similarly, the concentration or amount of eotaxin-3 DNA, eotaxin-3 mRNA, or eotaxin-3 protein over a normal amount in a patient tissue, such as blood or esophageal tissue, can be utilized further as an indicator of EE in the patient.

For evaluation of EE using clinical and/or physical assessment, biopsy tissues (obtained from the distal esophagus during routine endoscopy) were submerged in formalin for routine pathological analysis with hematoxylin and eosin staining. Diagnosis was established based on the maximum eosinophil count per high power field (hpf) and basal layer expansion according to method known in the art (e.g., established criteria in Rothenberg et al., Pathogenesis and clinical features of eosinophilic esophagitis. J Allergy Clin Immunol 108 (2001) 891; Attwood et al., Esophageal eosinophilia with dysphagia. A distinct clinicopathologic syndrome. Dig Dis Sci 38 (1993)109; Fox et al., Eosinophilic esophagitis: it's not just kid's stuff. Gastrointest Endosc 56 (2002) 26, each of which is expressly incorporated by reference herein in its entirety. Normal individuals (NL), n=13, served as a control and were defined as having 0 eosinophils/hpf and no basal layer expansion. Individuals with EE (n=76) were defined as having >24 eosinophils/hpf and extensive basal layer hyperplasia (expansion to about >⅓ of epithelium). Whole genome wide expression analysis demonstrated an EE transcriptome comprising 1620 genes. That is, 1620 genes were expressed significantly differently in EE patients compared to normal individuals, meaning that, at p<0.01, these 1620 genes from EE patients, using a patient pool size of 89, of which 76 patients had been diagnosed with EE, and 13 patients were individuals without EE, were either up-regulated or down-regulated by ≧1.5 fold, compared to normal individuals (NL). The data were analyzed by cluster analysis and ordered (standard correlation (A) and distance (B)) using Genespring software. Results are shown in FIG. 5 and Table 1. In FIG. 5, down-regulated genes were depicted in blue; and up-regulated genes were depicted in red, with the magnitude of the gene change proportional to the intensity of the blue and/or red colors. Each column represented a separate individual and each line a gene. RNA from each patient was subjected to chip analysis using Affymetrix Human Genome U133 GeneChip plus 2.

TABLE 1 The EE transcriptome Fold Genbank Accession SEQ ID Common Name Description Change number NO CCL26 Chemokine (C-C motif) ligand 26 62.73 NM_006072 1 TNFAIP6 Tumor necrosis factor, alpha-induced 42.94 NM_007115 2 protein 6 ALOX15 Arachidonate 15-lipoxygenase 36.11 NM_001140 3 APOBEC3A Apolipoprotein B mRNA editing enzyme, 24.37 NM_145699 4 catalytic polypeptide-like 3A POSTN Periostin, osteoblast specific factor 23.42 NM_006475 5 CDH26 Cadherin-like 26 23.28 NM_021810 6 CXCL1 Chemokine (C—X—C motif) ligand 1 20.89 NM_001511 7 (melanoma growth stimulating activity, alpha) NEFL Neurofilament, light polypeptide 68 kDa 17.68 NM_006158 8 TMEM16A Transmembrane protein 16A 17.5 NM_018043 9 SEQ_ID_#10 16.93 XM_293626 10 PMCH Pro-melanin-concentrating hormone 16.04 NM_002674 11 TMEM71 Hypothetical protein FLJ33069 15.06 NM_144649 12 CPA3 Carboxypeptidase A3 (mast cell) 14.51 NM_001870 13 LRRC31 Leucine rich repeat containing 31 12.48 NM_024727 14 IGLC2 Immunoglobulin lambda joining 3 12.33 AK057174 15 IGHD Immunoglobulin heavy constant delta 12.11 AK090461 16 SEQ_ID_#17 11.46 XM_097433 17 CLC Charcot-Leyden crystal protein 11.06 NM_001828 18 SEQ_ID_#19 10.29 NG_000002 19 CXCL6 Chemokine (C—X—C motif) ligand 6 10.24 NM_002993 20 (granulocyte chemotactic protein 2) SEC6L1 SEC6-like 1 (S. cerevisiae) 8.878 NM_007277 21 TCF12; HEB; HTF4; Homo sapiens mRNA; cDNA 8.833 BX647333 22 HsT17266 DKFZp686K1288 (from clone DKFZp686K1288). IGJ Immunoglobulin J polypeptide, linker 8.768 NM_144646 23 protein for immunoglobulin alpha and mu polypeptides C1orf178 Chromosome 1 open reading frame 178 8.681 NM_001010922 24 PHLDB2 Pleckstrin homology-like domain, family 8.485 NM_145753 25 B, member 2 GLDC Glycine dehydrogenase (decarboxylating; 8.382 NM_000170 26 glycine decarboxylase, glycine cleavage system protein P) EPPK1 Epiplakin 1 7.894 NM_031308 27 UBD Ubiquitin D 7.854 NM_006398 28 SUSD2 Sushi domain containing 2 7.725 NM_019601 29 CTSC synonyms: HMS, PLS, CPPI, DPP1, DPPI, 7.56 NM_148170 30 PALS; isoform b precursor is encoded by transcript variant 2; dipeptidyl-peptidase I; dipeptidyl transferase; cathepsin J; Papillon-Lefevre syndrome; go_component: lysosome [goid 0005764] [evidence TAS] [pmid 7665576]; go_function: dipeptidyl-peptidase I activity [goid 0004214] [evidence IEA]; go_function: cysteine-type endopeptidase activity [goid 0004197] [evidence IEA]; go_process: immune response [goid 0006955] [evidence TAS] [pmid 9092576]; go_process: proteolysis and peptidolysis [goid 0006508] [evidence NR]; Homo sapiens cathepsin C (CTSC), transcript variant 2, mRNA. TPSB2 Tryptase beta 2 7.199 NM_003294 31 SLC26A4 Solute carrier family 26, member 4 7.192 NM_000441 32 SAMSN1 SAM domain, SH3 domain and nuclear 7.119 NM_022136 33 localisation signals, 1 TRPM6 Transient receptor potential cation 6.979 NM_017662 34 channel, subfamily M, member 6 IF I factor (complement) 6.673 NM_000204 35 IL8 Interleukin 8 6.664 NM_000584 36 FLJ39117 Repetin 6.256 XM_371312 37 HRH1 Histamine receptor H1 6.208 NM_000861 38 MUC4 Mucin 4, tracheobronchial 6.139 NM_004532 39 KCNJ2 Potassium inwardly-rectifying channel, 6.061 NM_000891 40 subfamily J, member 2 IFRG28 28 kD interferon responsive protein 6.035 NM_022147 41 GPR160 G protein-coupled receptor 160 5.995 NM_014373 42 SEQ_ID_#43 Transcribed locus 5.944 CA314541 43 CA2 Carbonic anhydrase II 5.681 NM_000067 44 CD200R1 CD200 receptor 1 5.587 NM_138806 45 BF B-factor, properdin 5.507 NM_001710 46 SCUBE2 Signal peptide, CUB domain, EGF-like 2 5.502 NM_020974 47 MS4A2 Membrane-spanning 4-domains, 5.471 NM_000139 48 subfamily A, member 2 (Fc fragment of IgE, high affinity I, receptor for; beta polypeptide) MMP12 Matrix metalloproteinase 12 (macrophage 5.411 NM_002426 49 elastase) PGDS Prostaglandin D2 synthase, hematopoietic 5.312 NM_014485 50 SEQ_ID_#51 UI-H-DF1-aug-p-10-0-UI.s1 5.278 BM993907 51 NCI_CGAP_DF1 Homo sapiens cDNA clone IMAGE: 5869305 3′, mRNA sequence. SEQ_ID_#52 Transcribed locus 5.183 BQ004901 52 CHL1 Cell adhesion molecule with homology to 5.1 NM_006614 53 L1CAM (close homolog of L1) C9orf150 Chromosome 9 open reading frame 150 4.944 NM_203403 54 APOL1 Apolipoprotein L, 1 4.935 NM_003661 55 SEQ_ID_#56 LOC441801 4.841 BC037919 56 CH25H Cholesterol 25-hydroxylase 4.828 NM_003956 57 SEQ_ID_#58 4.822 XM_294092 58 SIDT1 Hypothetical protein FLJ21394 4.822 NM_017699 59 SLC28A3 Solute carrier family 28 (sodium-coupled 4.775 NM_022127 60 nucleoside transporter), member 3 UPK1B Uroplakin 1B 4.732 NM_006952 61 IL13RA2 Interleukin 13 receptor, alpha 2 4.636 NM_000640 62 PKP2 Plakophilin 2 4.627 NM_001005242 63 MSLN Mesothelin 4.616 NM_005823 64 SEQ_ID_#65 4.547 XM_059368 65 SLC6A14 Solute carrier family 6 (amino acid 4.539 NM_007231 66 transporter), member 14 NTRK2 Neurotrophic tyrosine kinase, receptor, 4.513 NM_001007097 67 type 2 VGLL1 Vestigial like 1 (Drosophila) 4.453 NM_016267 68 SPON1 Spondin 1, extracellular matrix protein 4.431 NM_006108 69 SEQ_ID_#70 UI-H-DF1-aug-p-10-0-UI.s1 4.409 BM993907 70 NCI_CGAP_DF1 Homo sapiens cDNA clone IMAGE: 5869305 3′, mRNA sequence. PRRX1 Paired related homeobox 1 4.375 NM_006902 71 SEQ_ID_#72 Transcribed locus 4.374 AW978130 72 SERPINB4 Serine (or cysteine) proteinase inhibitor, 4.328 NM_002974 73 clade B (ovalbumin), member 4 RGS13 Regulator of G-protein signalling 13 4.306 NM_002927 74 SLC16A1 AKR7 family pseudogene 4.285 NM_003051 75 LOC340061 Hypothetical protein LOC340061 4.211 NM_198282 76 TIMP1 Tissue inhibitor of metalloproteinase 1 4.158 NM_003254 77 (erythroid potentiating activity, collagenase inhibitor) SFRP1 Secreted frizzled-related protein 1 4.098 NM_003012 78 GCNT3 Glucosaminyl (N-acetyl) transferase 3, 4.078 NM_004751 79 mucin type SE57-1 CTCL tumor antigen se57-1 4.055 NM_025214 80 GRK5 G protein-coupled receptor kinase 5 3.995 NM_005308 81 SEQ_ID_#82 UI-H-DF1-aug-p-10-0-UI.s1 3.968 BM993907 82 NCI_CGAP_DF1 Homo sapiens cDNA clone IMAGE: 5869305 3′, mRNA sequence. ADRBK2 Adrenergic, beta, receptor kinase 2 3.932 NM_005160 83 HTR2B 5-hydroxytryptamine (serotonin) receptor 3.91 NM_000867 84 2B IFI35 Interferon-induced protein 35 3.885 NM_005533 85 IFI27 Interferon, alpha-inducible protein 27 3.873 NM_005532 86 LOC440449 Hypothetical gene supported by 3.856 XM_498675 87 AF086204 TPK1 Thiamin pyrophosphokinase 1 3.806 NM_022445 88 GALNT4 UDP-N-acetyl-alpha-D- 3.753 NM_003774 89 galactosamine:polypeptide N- acetylgalactosaminyltransferase 4 (GalNAc-T4) PDZK1IP1 PDZK1 interacting protein 1 3.677 NM_005764 90 LOC130576 Hypothetical protein LOC130576 3.669 NM_177964 91 SLC2A3 Solute carrier family 2 (facilitated glucose 3.657 NM_006931 92 transporter), member 3 FOXE1 Forkhead box E1 (thyroid transcription 3.65 NM_004473 93 factor 2) GABRP Gamma-aminobutyric acid (GABA) A 3.65 NM_014211 94 receptor, pi SEQ_ID_#95 Transcribed locus 3.633 BM988338 95 TNFSF13 Tumor necrosis factor (ligand) 3.62 NM_003808 96 superfamily, member 12 IGFBP3 Insulin-like growth factor binding protein 3 3.605 NM_000598 97 LHFPL2 Lipoma HMGIC fusion partner-like 2 3.591 NM_005779 98 CYP7B1 Cytochrome P450, family 7, subfamily B, 3.555 NM_004820 99 polypeptide 1 SLC18A2 Solute carrier family 18 (vesicular 3.541 NM_003054 100 monoamine), member 2 KITLG KIT ligand 3.538 NM_000899 101 LITAF Lipopolysaccharide-induced TNF factor 3.492 NM_004862 102 CDC42EP5 CDC42 effector protein (Rho GTPase 3.479 NM_145057 103 binding) 5 KRT23 Keratin 23 (histone deacetylase inducible) 3.475 NM_015515 104 EMILIN2 Elastin microfibril interfacer 2 3.473 NM_032048 105 TFPI Tissue factor pathway inhibitor 3.455 NM_006287 106 (lipoprotein-associated coagulation inhibitor) LOX Lysyl oxidase 3.448 NM_002317 107 PGBD5 PiggyBac transposable element derived 5 3.439 NM_024554 108 IL17RB Interleukin 17 receptor B 3.426 NM_018725 109 LOC91353 Similar to omega protein 3.416 NM_001013618 110 HS3ST1 Heparan sulfate (glucosamine) 3-O- 3.402 NM_005114 111 sulfotransferase 1 RARRES3 Retinoic acid receptor responder 3.397 NM_004585 112 (tazarotene induced) 3 HAS3 Decreased expression in renal and 3.391 NM_005329 113 prostate GPRC5B G protein-coupled receptor, family C, 3.384 NM_016235 114 group 5, member B NRXN1 Neurexin 1 3.372 NM_004801 115 SEQ_ID_#116 Transcribed locus 3.363 AW195474 116 LOXL4 Lysyl oxidase-like 4 3.336 NM_032211 117 PRG1 Proteoglycan 1, secretory granule 3.295 NM_002727 118 MFHAS1 Malignant fibrous histiocytoma amplified 3.29 NM_004225 119 sequence 1 SECTM1 Secreted and transmembrane 1 3.282 NM_003004 120 CISH Cytokine inducible SH2-containing protein 3.274 NM_145071 121 CFHL1 Complement factor H-related 1 3.251 NM_002113 122 pseudogene HDC Histidine decarboxylase 3.243 NM_002112 123 SIGLEC6 Sialic acid binding Ig-like lectin 6 3.199 NM_001245 124 GPR110 G protein-coupled receptor 110 3.193 NM_153840 125 SCIN Scinderin 3.17 NM_033128 126 SGK Serum/glucocorticoid regulated kinase 3.139 NM_005627 127 SH3RF2 SH3 domain containing ring finger 2 3.122 NM_152550 128 SH2D1B SH2 domain containing 1B 3.098 NM_053282 129 Cep72 Centrosomal protein 72 kDa 3.081 NM_018140 130 FETUB Fetuin B 3.065 NM_014375 131 RGS1 Regulator of G-protein signalling 1 3.056 NM_002922 132 APOBEC3B Apolipoprotein B mRNA editing enzyme, 3.039 NM_004900 133 catalytic polypeptide-like 3D MGC48998 Chromosome 1 open reading frame 110 3.036 NM_178550 134 CDH3 Cadherin 3, type 1, P-cadherin (placental) 3.026 NM_001793 135 DPYD Dihydropyrimidine dehydrogenase 3.015 NM_000110 136 EGLN3 Egl nine homolog 3 (C. elegans) 3.003 NM_022073 137 PTGES Prostaglandin E synthase 2.972 NM_004878 138 KIAA1126 KIAA1126 protein 2.944 AB032952 139 LOH11CR2A Loss of heterozygosity, 11, chromosomal 2.938 NM_198315 140 region 2, gene A CYP2S1 Cytochrome P450, family 2, subfamily S, 2.911 NM_030622 141 polypeptide 1 SEQ_ID_#142 UI-E-CL1-afe-h-18-0-UI.r1 UI-E-CL1 2.896 BM703543 142 Homo sapiens cDNA clone UI-E-CL1-afe- h-18-0-UI 5′, mRNA sequence. LBH Likely ortholog of mouse limb-bud and 2.895 NM_030915 143 heart gene MGC35033 Hypothetical protein MGC35033 2.875 NM_152319 144 CTSG Cathepsin G 2.869 NM_001911 145 SEQ_ID_#146 2.864 XM_375695 146 STOM Stomatin 2.846 NM_004099 147 PSMB9 Proteasome (prosome, macropain) 2.845 NM_002800 148 subunit, beta type, 9 (large multifunctional protease 2) ATF3 isoform 3 is encoded by transcript variant 2.844 NM_001030287 149 3; ATF3deltaZip3; ATF3deltaZip2c; go_component: nucleus [goid 0005634] [evidence IEA]; go_function: DNA binding [goid 0003677] [evidence IEA]; go_function: transcription factor activity [goid 0003700] [evidence TAS] [pmid 7515060]; go_function: transcription corepressor activity [goid 0003714] [evidence TAS] [pmid 7515060]; go_process: transcription [goid 0006350] [evidence IEA]; go_process: regulation of transcription, DNA-dependent [goid 0006355] [evidence IEA]; Homo sapiens activating transcription factor 3 (ATF3), transcript variant 3, mRNA. MMP28 Matrix metalloproteinase 28 2.839 NM_024302 150 SLC15A1 Solute carrier family 15 (oligopeptide 2.792 NM_005073 151 transporter), member 1 AIM2 Absent in melanoma 2 2.788 NM_004833 152 KIT V-kit Hardy-Zuckerman 4 feline sarcoma 2.776 NM_000222 153 viral oncogene homolog IL15 Interleukin 15 2.772 NM_000585 154 RASGRP1 RAS guanyl releasing protein 1 (calcium 2.769 NM_005739 155 and DAG-regulated) SLC27A2 Solute carrier family 27 (fatty acid 2.766 NM_003645 156 transporter), member 2 IFIT3 Interferon-induced protein with 2.763 NM_001549 157 tetratricopeptide repeats 3 LRRC8D Leucine rich repeat containing 8 family, 2.761 NM_018103 158 member D COL8A2 Collagen, type VIII, alpha 2 2.756 NM_005202 159 DUOX1 Dual oxidase 1 2.755 NM_017434 160 AYTL3 PLSC domain containing protein 2.749 NM_153613 161 F13A1 Coagulation factor XIII, A1 polypeptide 2.746 NM_000129 162 ACSL5 Acyl-CoA synthetase long-chain family 2.745 NM_016234 163 member 5 GCNT2 Glucosaminyl (N-acetyl) transferase 2, I- 2.742 NM_001491 164 branching enzyme SEQ_ID_#165 Transcribed locus, moderately similar to 2.732 BM929354 165 XP_517655.1 PREDICTED: similar to KIAA0825 protein [Pan troglodytes] TMPRSS4 Transmembrane protease, serine 4 2.719 NM_019894 166 MRC1 Mannose receptor, C type 1 2.717 NM_002438 167 NCF2 Neutrophil cytosolic factor 2 (65 kDa, 2.712 NM_000433 168 chronic granulomatous disease, autosomal 2) CSF2RB Colony stimulating factor 2 receptor, 2.707 NM_000395 169 beta, low-affinity (granulocyte- macrophage) GULP1 GULP, engulfment adaptor PTB domain 2.691 NM_016315 170 containing 1 SCUBE1 Signal peptide, CUB domain, EGF-like 1 2.689 NM_173050 171 NFE2L3 Nuclear factor (erythroid-derived 2)-like 3 2.688 NM_004289 172 PSMB8 Proteasome (prosome, macropain) 2.687 NM_004159 173 subunit, beta type, 8 (large multifunctional protease 7) LY96 Lymphocyte antigen 96 2.678 NM_015364 174 PSTPIP2 Proline-serine-threonine phosphatase 2.675 NM_024430 175 interacting protein 2 CTSS Cathepsin S 2.67 NM_004079 176 GGH Gamma-glutamyl hydrolase (conjugase, 2.665 NM_003878 177 folylpolygammaglutamyl hydrolase) SERPINE2 Serine (or cysteine) proteinase inhibitor, 2.66 NM_006216 178 clade E (nexin, plasminogen activator inhibitor type 1), member 2 GALNT5 UDP-N-acetyl-alpha-D- 2.648 NM_014568 179 galactosamine:polypeptide N- acetylgalactosaminyltransferase 5 (GalNAc-T5) CNTN4 Contactin 4 2.643 NM_175607 180 TPPP Brain-specific protein p25 alpha 2.639 NM_007030 181 ZDHHC11 Zinc finger, DHHC-type containing 11 2.631 NM_024786 182 BCL2A1 BCL2-related protein A1 2.621 NM_004049 183 GRM7 Glutamate receptor, metabotropic 7 2.62 BC009905 184 SEQ_ID_#185 UI-H-BI4-apt-c-08-0-UI.s1 2.62 BF511924 185 NCI_CGAP_Sub8 Homo sapiens cDNA clone IMAGE: 3088503 3′, mRNA sequence. SEQ_ID_#186 Transcribed locus 2.617 BF025845 186 TSPAN3 Tetraspanin 3 2.614 NM_005724 187 ADAM28 A disintegrin and metalloproteinase 2.613 NM_014265 188 domain 28 SEPX1 Selenoprotein X, 1 2.611 NM_016332 189 IL27RA Interleukin 27 receptor, alpha 2.606 NM_004843 190 NAV1 Neuron navigator 1 2.603 NM_020443 191 MET Met proto-oncogene (hepatocyte growth 2.592 NM_000245 192 factor receptor) SEQ_ID_#193 cs100c01.y1 Human Retinal pigment 2.591 CA389545 193 epithelium/choroid cDNA (Un-normalized, unamplified): cs Homo sapiens cDNA clone cs100c01 5′, mRNA sequence. SOCS3 Suppressor of cytokine signaling 3 2.589 NM_003955 194 ID3 Inhibitor of DNA binding 3, dominant 2.584 NM_002167 195 negative helix-loop-helix protein BID BH3 interacting domain death agonist 2.582 NM_001196 196 THEDC1 Thioesterase domain containing 1 2.568 NM_018324 197 LR8 LR8 protein 2.564 NM_014020 198 CEL Carboxyl ester lipase (bile salt-stimulated 2.557 NM_001807 199 lipase) CALML4 2.555 NM_001031733 200 LOC387882 LOC387882 hypothetical protein 2.551 NM_207376 201 NEK6 NIMA (never in mitosis gene a)-related 2.513 NM_014397 202 kinase 6 NCF1 Neutrophil cytosolic factor 1 (47 kDa, 2.509 NM_000265 203 chronic granulomatous disease, autosomal 1) DDX58 DEAD (Asp-Glu-Ala-Asp) box polypeptide 2.506 NM_014314 204 58 CLDN23 Claudin 23 2.505 NM_194284 205 FA2H Fatty acid 2-hydroxylase 2.497 NM_024306 206 LOC286002 Hypothetical protein LOC286002 2.483 BC037315 207 IFITM3 Interferon induced transmembrane 2.456 NM_021034 208 protein 3 (1-8U) MDK Midkine (neurite growth-promoting factor 2.45 NM_001012333 209 2) KIAA1337 Patched domain containing 2 2.445 XM_052561 210 VDR Vitamin D (1,25-dihydroxyvitamin D3) 2.441 NM_000376 211 receptor MGC14595 Hypothetical protein MGC14595 2.44 NM_032334 212 CHKB Choline kinase beta 2.433 NM_152253 213 APOL3 Apolipoprotein L, 3 2.426 NM_014349 214 EDAR Ectodysplasin A receptor 2.425 NM_022336 215 SEQ_ID_#216 CDNA FLJ31134 fis, clone IMR322000984 2.423 AK095590 216 BRDG1 BCR downstream signaling 1 2.418 NM_012108 217 FMO1 Flavin containing monooxygenase 1 2.412 NM_002021 218 ASS Argininosuccinate synthetase 2.41 NM_000050 219 GPRC5A G protein-coupled receptor, family C, 2.406 NM_003979 220 group 5, member A LOC113179 Secretory carrier membrane protein 4 2.403 NM_138422 221 TAPBP TAP binding protein (tapasin) 2.401 NM_003190 222 UTS2 Urotensin 2 2.401 NM_006786 223 LYPDC1 LY6/PLAUR domain containing 1 2.399 NM_144586 224 MICB MHC class I polypeptide-related sequence B 2.394 NM_005931 225 GPX4 Glutathione peroxidase 4 (phospholipid 2.393 NM_002085 226 hydroperoxidase) TMCC3 Transmembrane and coiled-coil domain 2.39 NM_020698 227 family 3 TRIM22 Tripartite motif-containing 22 2.387 NM_006074 228 SUV420H1 Suppressor of variegation 4-20 homolog 2.384 NM_017635 229 1 (Drosophila) CFH Complement factor H 2.383 NM_001014975 230 FLJ41603 FLJ41603 protein 2.378 NM_001001669 231 SLC4A11 Solute carrier family 4, sodium 2.363 NM_032034 232 bicarbonate transporter-like, member 11 C1QB Complement component 1, q 2.351 NM_000491 233 subcomponent, beta polypeptide FLJ35880 Hypothetical protein FLJ35880 2.349 NM_153264 234 IGLL3; 16.1 Human germline gene 16.1 for Ig lambda 2.342 X03529 235 L-chain C region (IgL-C16.1). SEQ_ID_#239 yc17g11.s1 Stratagene lung (#937210) 2.342 T70087 236 Homo sapiens cDNA clone IMAGE: 80996 3′, mRNA sequence. PLAUR Plasminogen activator, urokinase receptor 2.334 NM_001005377 237 OR2A20P Olfactory receptor, family 2, subfamily A, 2.327 BC016940 238 member 20 pseudogene MAP3K14 Mitogen-activated protein kinase kinase 2.318 NM_003954 239 kinase 14 GATA2 GATA binding protein 2 2.315 NM_032638 240 BIRC4BP XIAP associated factor-1 2.315 NM_017523 241 LOC388610 Hypothetical LOC388610 2.311 NM_001013642 242 SEQ_ID_#243 AGENCOURT_6466806 NIH_MGC_88 2.308 BM479034 243 Homo sapiens cDNA clone IMAGE: 5561432 5′, mRNA sequence. SOCS1 Suppressor of cytokine signaling 1 2.306 NM_003745 244 SEQ_ID_#245 oc22e04.s1 NCI_CGAP_GCB1 Homo 2.303 AA806368 245 sapiens cDNA clone IMAGE: 1350462 3′ similar to contains Alu repetitive element; contains element PTR5 repetitive element;, mRNA sequence. SDPR Serum deprivation response 2.293 NM_004657 246 (phosphatidylserine binding protein) HLF Hepatic leukemia factor 2.283 NM_002126 247 SCARA3 Scavenger receptor class A, member 3 2.282 NM_182826 248 SMILE SMILE protein 2.28 NM_181783 249 FGG Fibrinogen gamma chain 2.272 NM_021870 250 IFITM1 Interferon induced transmembrane 2.269 NM_003641 251 protein 1 (9-27) CASP7 Caspase 7, apoptosis-related cysteine 2.266 NM_001227 252 protease SEQ_ID_#253 Transcribed locus 2.264 CA306881 253 PSMB10 Proteasome (prosome, macropain) 2.261 NM_002801 254 subunit, beta type, 10 UCP2 Uncoupling protein 2 (mitochondrial, 2.259 NM_003355 255 proton carrier) IGSF4 Immunoglobulin superfamily, member 4 2.258 NM_014333 256 RARB Retinoic acid receptor, beta 2.253 NM_000965 257 LRP1 Low density lipoprotein-related protein 1 2.248 NM_002332 258 (alpha-2-macroglobulin receptor) IFITM2 Interferon induced transmembrane 2.244 NM_006435 259 protein 2 (1-8D) PARP14 Poly (ADP-ribose) polymerase family, 2.243 NM_017554 260 member 14 SOS1 Son of sevenless homolog 1 (Drosophila) 2.243 NM_005633 261 NTRK3 Neurotrophic tyrosine kinase, receptor, 2.24 NM_002530 262 type 3 PRICKLE2 Prickle-like 2 (Drosophila) 2.237 NM_198859 263 ARMCX3 Armadillo repeat containing, X-linked 3 2.234 NM_016607 264 ECGF1 Endothelial cell growth factor 1 (platelet- 2.221 NM_001953 265 derived) TNS4 Tensin 4 2.216 NM_032865 266 FBXO6 F-box protein 6 2.216 NM_018438 267 APOL2 Apolipoprotein L, 2 2.213 NM_030882 268 LY75 Lymphocyte antigen 75 2.212 NM_002349 269 C10orf128 Chromosome 10 open reading frame 128 2.198 BC047724 270 RRM2 Ribonucleotide reductase M2 polypeptide 2.197 NM_001034 271 GPCR5A G protein-coupled receptor, family C, 2.197 NM_003979 272 group 5, member A HSPA5BP1 Heat shock 70 kDa protein 5 (glucose- 2.193 NM_017870 273 regulated protein, 78 kDa) binding protein 1 GLCCI1; GIG18 synonym: GIG18; Homo sapiens 2.191 XM_166529 274 glucocorticoid induced transcript 1 (GLCCI1), mRNA. CD52 CD52 antigen (CAMPATH-1 antigen) 2.184 NM_001803 275 ADA Adenosine deaminase 2.183 NM_000022 276 CXCL16 Chemokine (C—X—C motif) ligand 16 2.179 NM_022059 277 IFIH1 Interferon induced with helicase C domain 1 2.174 NM_022168 278 ZSWIM5 Zinc finger, SWIM-type containing 5 2.169 XM_046581 279 VMP1 Transmembrane protein 49 2.168 NM_030938 280 UBE2L6 Ubiquitin-conjugating enzyme E2L 6 2.164 NM_004223 281 ARHGAP8; PRR5; Rho GTPase activating protein 8 2.164 NM_017701 282 PP610; BPGAP1; FLJ20185 IRF1 Interferon regulatory factor 1 2.161 NM_002198 283 C1orf188 Hypothetical protein FLJ32096 2.157 NM_173795 284 IFI30 Interferon, gamma-inducible protein 30 2.155 NM_006332 285 PLCD3 Phospholipase C, delta 3 2.152 NM_133373 286 WFDC5 WAP four-disulfide core domain 5 2.148 NM_145652 287 SEQ_ID_#288 AGENCOURT_8217637 2.146 BQ717725 288 Lupski_sympathetic_trunk Homo sapiens cDNA clone IMAGE: 6187901 5′, mRNA sequence. SIGLECP3 Sialic acid binding Ig-like lectin, 2.144 BC035688 289 pseudogene 3 IFPS Ifapsoriasin 2.142 NM_001014342 290 CD14 CD14 antigen 2.138 NM_000591 291 LOC441168 Hypothetical protein LOC441168 2.136 NM_001010919 292 FCER1G Fc fragment of IgE, high affinity I, 2.135 NM_004106 293 receptor for; gamma polypeptide CD44 CD44 antigen (homing function and 2.132 NM_000610 294 Indian blood group system) SEQ_ID_#295 CDNA FLJ44380 fis, clone TRACH3035482 2.128 AK126351 295 STAB1 Stabilin 1 2.127 NM_015136 296 ITGAM Integrin, alpha M (complement 2.126 NM_000632 297 component receptor 3, alpha; also known as CD11b (p170), macrophage antigen alpha polypeptide) CBX6 Chromobox homolog 6 2.126 NM_014292 298 CYP2E1 Cytochrome P450, family 2, subfamily E, 2.118 NM_000773 299 polypeptide 1 C1orf74 Chromosome 1 open reading frame 74 2.117 NM_152485 300 LILRB1 Leukocyte immunoglobulin-like receptor, 2.115 NM_006669 301 subfamily B (with TM and ITIM domains), member 1 BAK1 BCL2-antagonist/killer 1 2.114 NM_001188 302 HCP5 HLA complex P5 2.113 NM_006674 303 PLA2G3 Phospholipase A2, group III 2.112 NM_015715 304 NXN Nucleoredoxin 2.107 NM_022463 305 RRAS Related RAS viral (r-ras) oncogene 2.094 NM_006270 306 homolog ESR1 Estrogen receptor 1 2.088 NM_000125 307 LOC152485 Hypothetical protein LOC152485 2.086 NM_178835 308 PITX2 Paired-like homeodomain transcription 2.085 NM_000325 309 factor 2 SLCO3A1 Solute carrier organic anion transporter 2.081 NM_013272 310 family, member 3A1 PARP12 Poly (ADP-ribose) polymerase family, 2.078 NM_022750 311 member 12 TAP1 Transporter 1, ATP-binding cassette, sub- 2.076 NM_000593 312 family B (MDR/TAP) SEQ_ID_#313 Transcribed locus 2.075 BU689688 313 RPRC1 Arginine/proline rich coiled-coil 1 2.074 NM_018067 314 BTN3A3 Butyrophilin, subfamily 3, member A3 2.073 NM_006994 315 UBE1L Ubiquitin-activating enzyme E1-like 2.07 NM_003335 316 RRAD Ras-related associated with diabetes 2.069 NM_004165 317 PLCE1 Phospholipase C, epsilon 1 2.069 NM_016341 318 SEQ_ID_#319 601123374F1 NIH_MGC_5 Homo sapiens 2.069 BE749174 319 cDNA clone IMAGE: 3348067 5′, mRNA sequence. CAPN14 Calpain 14 2.067 AK092257 320 ELOVL5 ELOVL family member 5, elongation of 2.065 NM_021814 321 long chain fatty acids (FEN1/Elo2, SUR4/Elo3-like, yeast) GPR143 G protein-coupled receptor 143 2.06 NM_000273 322 SMTN Smoothelin 2.046 NM_134269 323 FLJ14466 Hypothetical protein FLJ14466 2.045 NM_032790 324 LOC285016; synonyms: PRO1097, RGPG542; Homo 2.045 XM_211736 325 PRO1097; RGPG542 sapiens hypothetical protein LOC285016 (LOC285016), mRNA. APOL6 Apolipoprotein L, 6 2.042 NM_030641 326 ADAM8 A disintegrin and metalloproteinase 2.041 NM_001109 327 domain 8 C1orf186 Hypothetical gene supported by 2.035 NM_001007544 328 AK122631; BC071785 ABHD4 Abhydrolase domain containing 4 2.03 NM_022060 329 GSDML Gasdermin-like 2.029 NM_018530 330 SEQ_ID_#331 UI-H-BI4-apu-h-06-0-UI.s1 2.029 BF512055 331 NCI_CGAP_Sub8 Homo sapiens cDNA clone IMAGE: 3088762 3′, mRNA sequence. MYCPBP C-myc promoter binding protein 2.028 NM_005848 332 C1QA Complement component 1, q 2.023 NM_015991 333 subcomponent, alpha polypeptide SLC16A2 Solute carrier family 16 (monocarboxylic 2.019 NM_006517 334 acid transporters), member 2 C10orf47 Chromosome 10 open reading frame 47 2.019 NM_153256 335 GBP4 Guanylate binding protein 4 2.018 NM_052941 336 ARHGEF6 Rac/Cdc42 guanine nucleotide exchange 2.013 NM_004840 337 factor (GEF) 6 LILRB2 Leukocyte immunoglobulin-like receptor, 2.012 NM_005874 338 subfamily B (with TM and ITIM domains), member 2 SEQ_ID_#339 2.009 AL121896 339 NFKBIE Nuclear factor of kappa light polypeptide 2.007 NM_004556 340 gene enhancer in B-cells inhibitor, epsilon SEQ_ID_#341 EST387291 MAGE resequences, MAGN 2.007 AW975183 341 Homo sapiens cDNA, mRNA sequence. EHD2 EH-domain containing 2 2.004 NM_014601 342 CCDC34 NY-REN-41 antigen 2.004 NM_030771 343 BAZ2A Bromodomain adjacent to zinc finger 1.992 NM_013449 344 domain, 2A CAPN3 Glucosidase, alpha; neutral C 1.989 NM_000070 345 MVP Major vault protein 1.988 NM_005115 346 SIGLEC10 Sialic acid binding Ig-like lectin 10 1.988 NM_033130 347 ARID5B AT rich interactive domain 5B (MRF1-like) 1.988 AI289774 348 ZC3H12A Zinc finger CCCH-type containing 12A 1.987 NM_025079 349 AP2M1 Adaptor-related protein complex 2, mu 1 1.982 NM_001025205 350 subunit MX1 Myxovirus (influenza virus) resistance 1, 1.98 NM_002462 351 interferon-inducible protein p78 (mouse) PDLIM4 PDZ and LIM domain 4 1.977 NM_003687 352 OAS2 2′-5′-oligoadenylate synthetase 2, 1.974 NM_016817 353 69/71 kDa MKI67 Antigen identified by monoclonal antibody 1.971 NM_002417 354 Ki-67 RBPMS RNA binding protein with multiple splicing 1.971 NM_001008710 355 PARP9 Poly (ADP-ribose) polymerase family, 1.968 NM_031458 356 member 9 ABCC5 ATP-binding cassette, sub-family C 1.961 NM_005688 357 (CFTR/MRP), member 5 CLDN1 Claudin 1 1.961 AV659222 358 T3JAM TRAF3 interacting protein 3 1.958 NM_025228 359 IKBKAP Inhibitor of kappa light polypeptide gene 1.955 NM_003640 360 enhancer in B-cells, kinase complex- associated protein FAM46A Family with sequence similarity 46, 1.955 NM_017633 361 member A CHST9 Carbohydrate (N-acetylgalactosamine 4- 1.954 NM_031422 362 0) sulfotransferase 9 KIAA1272 Chromosome 20 open reading frame 74 1.953 AY007156 363 NIP Homolog of Drosophila Numb-interacting 1.953 NM_144565 364 protein DRAP1 Similar to ankyrin 1.951 BC018095 365 SART2 Squamous cell carcinoma antigen 1.951 NM_013352 366 recognized by T cells 2 SPBC25 Spindle pole body component 25 homolog 1.95 NM_020675 367 (S. cerevisiae) NFATC2 Nuclear factor of activated T-cells, 1.949 NM_173091 368 cytoplasmic, calcineurin-dependent 2 SLC9A3 Solute carrier family 9 (sodium/hydrogen 1.948 AL137723 369 exchanger), isoform 3 SEQ_ID_#370 CDNA: FLJ23006 fis, clone LNG00414 1.948 AK026659 370 C6orf173 Chromosome 6 open reading frame 173 1.946 NM_001012507 371 CYP4X1 Cytochrome P450, family 4, subfamily X, 1.946 NM_178033 372 polypeptide 1 DUSP10 Dual specificity phosphatase 10 1.945 NM_007207 373 PTPN6 Protein tyrosine phosphatase, non- 1.943 NM_002831 374 receptor type 6 FGF11 Fibroblast growth factor 11 1.94 NM_004112 375 NFIL3 Nuclear factor, interleukin 3 regulated 1.939 NM_005384 376 CMYA5 Cardiomyopathy associated 5 1.938 NM_153610 377 MGC4677 Hypothetical protein MGC4677 1.938 NM_052871 378 KCNE3 Potassium voltage-gated channel, Isk- 1.937 NM_005472 379 related family, member 3 WHSC1 Wolf-Hirschhorn syndrome candidate 1 1.936 BF509385 380 NCF4 Neutrophil cytosolic factor 4, 40 kDa 1.935 NM_000631 381 CD300LF CD300 antigen like family member F 1.934 NM_139018 382 TMC6 Epidermodysplasia verruciformis 1 1.93 NM_007267 383 AP1G2 Adaptor-related protein complex 1, 1.929 NM_003917 384 gamma 2 subunit MGC4368 1.924 NM_001033046 385 LOC441109 Hypothetical gene supported by 1.923 XM_499014 386 AL713721 LAPTM5 Lysosomal associated multispanning 1.923 NM_006762 387 membrane protein 5 SEQ_ID_#388 BX438987 Homo sapiens PLACENTA 1.921 BX438987 388 Homo sapiens cDNA clone CS0DE005YG01 3-PRIME, mRNA sequence. ELF4 E74-like factor 4 (ets domain 1.92 NM_001421 389 transcription factor) ARHGEF5 Rho guanine nucleotide exchange factor 1.919 NM_001002861 390 (GEF) 5 PRODH Proline dehydrogenase (oxidase) 1 1.913 NM_016335 391 GALNAC4S-6ST B cell RAG associated protein 1.913 NM_015892 392 MGC17791 Tumor necrosis factor, alpha-induced 1.912 NM_152362 393 protein 8-like 1 BIK BCL2-interacting killer (apoptosis- 1.911 NM_001197 394 inducing) FAM54A Family with sequence similarity 54, 1.911 NM_138419 395 member A VWA1 Von Willebrand factor A domain 1.91 NM_022834 396 containing 1 LOC401115 Hypothetical gene supported by 1.909 XM_379250 397 BC038466; BC062790 CD40 CD40 antigen (TNF receptor superfamily 1.907 NM_001250 398 member 5) L3MBTL L(3)mbt-like (Drosophila) 1.907 NM_015478 399 SAA2 Serum amyloid A2 1.907 NM_030754 400 ECT2 Epithelial cell transforming sequence 2 1.907 NM_018098 401 oncogene MOV10 Mov10, Moloney leukemia virus 10, 1.903 NM_020963 402 homolog (mouse) FLJ21103 Hypothetical protein FLJ21103 1.903 NM_024556 403 KLRK1 Killer cell lectin-like receptor subfamily K, 1.9 NM_007360 404 member 1 SEQ_ID_#405 CDNA FLJ44429 fis, clone UTERU2015653 1.9 AJ318805 405 SCOTIN Scotin 1.899 NM_016479 406 WDR51B WD repeat domain 51B 1.896 NM_172240 407 FLT3LG Fms-related tyrosine kinase 3 ligand 1.896 NM_001459 408 KIAA0493 KIAA0493 protein 1.89 AB007962 409 LTA4H Leukotriene A4 hydrolase 1.888 NM_000895 410 USP54 Ubiquitin specific protease 54 1.888 NM_152586 411 TACC3 Transforming, acidic coiled-coil containing 1.888 NM_006342 412 protein 3 LGALS3BP Lectin, galactoside-binding, soluble, 3 1.888 NM_005567 413 binding protein LOC440288 Similar to FLJ16518 protein 1.887 XM_496075 414 G0S2 Putative lymphocyte G0/G1 switch gene 1.887 NM_015714 415 CCBL1 Cysteine conjugate-beta lyase; 1.884 NM_004059 416 cytoplasmic (glutamine transaminase K, kyneurenine aminotransferase) RGS19 Regulator of G-protein signalling 19 1.883 NM_005873 417 KLHL5 Kelch-like 5 (Drosophila) 1.883 NM_001007075 418 VILL Villin-like 1.883 NM_015873 419 GLCCI1 Glucocorticoid induced transcript 1 1.881 NM_138426 420 TYROBP TYRO protein tyrosine kinase binding 1.879 NM_003332 421 protein CDC2 Cell division cycle 2, G1 to S and G2 to M 1.879 NM_001786 422 LOC158402 Hypothetical protein LOC158402 1.878 AK095652 423 PRSS12 Protease, serine, 12 (neurotrypsin, 1.878 NM_003619 424 motopsin) SEQ_ID_#425 Transcribed locus 1.877 AI632517 425 FAM20C Family with sequence similarity 20, 1.875 NM_020223 426 member C GBP2 Guanylate binding protein 2, interferon- 1.868 NM_004120 427 inducible SEQ_ID_#428 CDNA FLJ45384 fis, clone BRHIP3021987 1.866 AK127315 428 HIST3H2A Histone 3, H2a 1.866 NM_033445 429 OLFML2A Olfactomedin-like 2A 1.864 NM_182487 430 TNFSF10 Tumor necrosis factor (ligand) 1.862 NM_003810 431 superfamily, member 10 LOC120376 Hypothetical protein LOC120376 1.858 XM_071712 432 EPHA4 EPH receptor A4 1.858 NM_004438 433 DERL2 Der1-like domain family, member 2 1.856 NM_016041 434 CYP2R1 Cytochrome P450, family 2, subfamily R, 1.852 NM_024514 435 polypeptide 1 VSNL1 Visinin-like 1 1.85 NM_003385 436 MGAT3 Mannosyl (beta-1,4-)-glycoprotein beta- 1.85 NM_002409 437 1,4-N-acetylglucosaminyltransferase CLMN Calmin (calponin-like, transmembrane) 1.846 NM_024734 438 HES2 Hairy and enhancer of split 2 (Drosophila) 1.841 NM_019089 439 SEQ_ID_#440 LOC441069 1.84 AK056817 440 DDX39 DEAD (Asp-Glu-Ala-Asp) box polypeptide 1.839 NM_005804 441 39 SEQ_ID_#442 Transcribed locus 1.839 AW979271 442 PARP8 Poly (ADP-ribose) polymerase family, 1.838 NM_024615 443 member 8 CLN5 Ceroid-lipofuscinosis, neuronal 5 1.835 NM_006493 444 HLA-B Major histocompatibility complex, class I, B 1.834 NM_005514 445 RAB34 RAB34, member RAS oncogene family 1.834 NM_031934 446 BTK Bruton agammaglobulinemia tyrosine 1.832 NM_000061 447 kinase AMICA1 Adhesion molecule, interacts with CXADR 1.83 NM_153206 448 antigen 1 SEQ_ID_#449 Transcribed locus 1.83 BG771234 449 SEQ_ID_#450 Transcribed locus, weakly similar to 1.829 BG483393 450 XP_517655.1 PREDICTED: similar to KIAA0825 protein [Pan troglodytes] TNFRSF10B Tumor necrosis factor receptor 1.826 NM_003842 451 superfamily, member 10b CEACAM1 Carcinoembryonic antigen-related cell 1.821 NM_001024912 452 adhesion molecule 1 (biliary glycoprotein) EGFL6 EGF-like-domain, multiple 6 1.821 NM_015507 453 VAMP5 Vesicle-associated membrane protein 5 1.82 NM_006634 454 (myobrevin) FLT1 Fms-related tyrosine kinase 1 (vascular 1.82 NM_002019 455 endothelial growth factor/vascular permeability factor receptor) SEQ_ID_#456 Transcribed locus, weakly similar to 1.819 BQ010718 456 XP_498452.1 PREDICTED: hypothetical protein XP_498452 [Homo sapiens] GPR82 G protein-coupled receptor 82 1.819 BX438968 457 UQCRC1 Ubiquinol-cytochrome c reductase core 1.818 NM_003365 458 protein I RNASE1 Ribonuclease, RNase A family, 1 1.818 NM_002933 459 (pancreatic) NOD27 Nucleotide-binding oligomerization 1.817 NM_032206 460 domains 27 PTPNS1 Protein tyrosine phosphatase, non- 1.817 NM_080792 461 receptor type substrate 1 3′HEXO Three prime histone mRNA exonuclease 1 1.817 NM_153332 462 C3AR1 Complement component 3a receptor 1 1.815 NM_004054 463 ITPR3 Inositol 1,4,5-triphosphate receptor, type 3 1.813 NM_002224 464 LRRC8A Leucine rich repeat containing 8 family, 1.81 NM_019594 465 member A ST8SIA6; SIAT8F; synonyms: SIAT8F, ST8SIA-VI, ST8Sia 1.81 XM_291725 466 ST8SIA-VI; ST8Sia VI; sialyltransferase 8F; sialyltransferase VI 8F (alpha-2, 8-sialyltransferase); go_component: membrane [goid 0016020] [evidence IEA]; go_component: Golgi stack [goid 0005795] [evidence IEA]; go_component: integral to membrane [goid 0016021] [evidence IEA]; go_function: sialyltransferase activity [goid 0008373] [evidence IEA]; go_process: protein amino acid glycosylation [goid 0006486] [evidence IEA]; Homo sapiens ST8 alpha-N-acetyl- neuraminide alpha-2,8-sialyltransferase 6 (ST8SIA6), mRNA. C17orf27 Chromosome 17 open reading frame 27 1.808 NM_020914 467 FBXL18 F-box and leucine-rich repeat protein 18 1.808 NM_024963 468 FOXQ1 Forkhead box Q1 1.807 NM_033260 469 CXorf9 Chromosome X open reading frame 9 1.807 NM_018990 470 TAPBPL TAP binding protein-like 1.805 NM_018009 471 FAM50A Family with sequence similarity 50, 1.805 NM_004699 472 member A GGA2 Golgi associated, gamma adaptin ear 1.805 NM_015044 473 containing, ARF binding protein 2 TLOC1 Translocation protein 1 1.802 NM_003262 474 HLA-E Major histocompatibility complex, class I, E 1.801 NM_005516 475 SEQ_ID_#476 Transcribed locus 1.8 BM999272 476 TTMP TPA-induced transmembrane protein 1.798 NM_024616 477 SEQ_ID_#479 CDNA FLJ39947 fis, clone SPLEN2024232 1.798 AK097266 478 SLC39A8 Solute carrier family 39 (zinc 1.796 NM_022154 479 transporter), member 8 E2F2 E2F transcription factor 2 1.796 NM_004091 480 NUP210 Nucleoporin 210 kDa 1.796 NM_024923 481 PPAP2C Phosphatidic acid phosphatase type 2C 1.795 NM_003712 482 EHMT2 Euchromatic histone-lysine N- 1.793 NM_006709 483 methyltransferase 2 RYR2 Ryanodine receptor 2 (cardiac) 1.793 NM_001035 484 IL15RA Interleukin 15 receptor, alpha 1.793 NM_002189 485 STK6 Serine/threonine kinase 6 1.793 NM_003600 486 LAMB3 Laminin, beta 3 1.792 NM_000228 487 SPTBN1 Spectrin, beta, non-erythrocytic 1 1.792 NM_003128 488 ETV6 Ets variant gene 6 (TEL oncogene) 1.791 NM_001987 489 PSMB7 Proteasome (prosome, macropain) 1.791 NM_002799 490 subunit, beta type, 7 HMGB3 synonyms: HMG4, HMG2A, MGC90319; 1.79 NM_005342 491 high-mobility group (nonhistone chromosomal) protein 4; non-histone chromosomal protein; go_component: nucleus [goid 0005634] [evidence IEA]; go_component: chromatin [goid 0000785] [evidence IEA]; go_function: DNA binding [goid 0003677] [evidence IEA]; go_function: DNA bending activity [goid 0008301] [evidence TAS] [pmid 9598312]; go_process: development [goid 0007275] [evidence TAS] [pmid 9598312]; go_process: regulation of transcription, DNA-dependent [goid 0006355] [evidence IEA]; Homo sapiens high-mobility group box 3 (HMGB3), mRNA. DOK3 Docking protein 3 1.79 NM_024872 492 DNAPTP6 DNA polymerase-transactivated protein 6 1.787 NM_015535 493 LOC285835 Hypothetical protein LOC285835 1.787 BC035656 494 CDC20 CDC20 cell division cycle 20 homolog (S. cerevisiae) 1.781 NM_001255 495 SEQ_ID_#496 AGENCOURT_7258511 NIH_MGC_71 1.781 BQ219651 496 Homo sapiens cDNA clone IMAGE: 5786579 5′, mRNA sequence. TNFRSF10A Tumor necrosis factor receptor 1.78 NM_003844 497 superfamily, member 10a KIF4A Kinesin family member 4A 1.779 NM_012310 498 SEQ_ID_#499 UI-CF-FN0-afk-f-10-0-UI.s1 UI-CF-FN0 1.777 CA312567 499 Homo sapiens cDNA clone UI-CF-FN0-afk- f-10-0-UI 3′, mRNA sequence. SDF2 Stromal cell-derived factor 2 1.776 NM_006923 500 PCCA Propionyl Coenzyme A carboxylase, alpha 1.776 NM_000282 501 polypeptide TM7SF1 Transmembrane 7 superfamily member 1 1.774 NM_003272 502 (upregulated in kidney) DKFZP564K1964 1.773 NM_001033504 503 VSIG4 V-set and immunoglobulin domain 1.771 NM_007268 504 containing 4 TNIP2 TNFAIP3 interacting protein 2 1.77 NM_024309 505 KIAA0513 KIAA0513 1.768 NM_014732 506 PPM1M Protein phosphatase 1M (PP2C domain 1.767 NM_144641 507 containing) EXOC3 SEC6-like 1 (S. cerevisiae) 1.767 NM_007277 508 PSME2 Proteasome (prosome, macropain) 1.767 NM_002818 509 activator subunit 2 (PA28 beta) RAB7 RAB7, member RAS oncogene family 1.766 NM_004637 510 SEQ_ID_#511 CDNA clone IMAGE: 6043059 1.764 BC039021 511 TNFRSF14 Tumor necrosis factor receptor 1.763 NM_003820 512 superfamily, member 14 (herpesvirus entry mediator) KRT4 Keratin 4 1.762 NM_002272 513 CST3 Cystatin C (amyloid angiopathy and 1.761 NM_000099 514 cerebral hemorrhage) MGC19764 Hypothetical protein MGC19764 1.756 NM_144975 515 NUP50 Nucleoporin 50 kDa 1.756 NM_007172 516 SFXN1 Sideroflexin 1 1.754 NM_022754 517 BIRC5 Effector cell protease receptor 1 1.753 NM_001012270 518 IL2RG Interleukin 2 receptor, gamma (severe 1.753 NM_000206 519 combined immunodeficiency) RIPK2 Receptor-interacting serine-threonine 1.751 NM_003821 520 kinase 2 SEQ_ID_#521 Non-coding transcript, polyA signal, clone 1.75 BC040308 521 44-5SB/3L RTKN Rhotekin 1.75 NM_001015055 522 NDFIP2 Nedd4 family interacting protein 2 1.749 NM_019080 523 ARRDC2 Arrestin domain containing 2 1.749 NM_001025604 524 EFHD2 EF-hand domain family, member D2 1.747 NM_024329 525 C9orf127 Chromosome 9 open reading frame 127 1.747 NM_016446 526 KIAA1509 KIAA1509 1.747 XM_029353 527 ACPL2 1.744 NM_001037172 528 SEQ_ID_#529 LOC441069 1.742 AK056817 529 FAM100B Hypothetical protein MGC29814 1.742 NM_182565 530 BTG3 BTG family, member 3 1.741 NM_006806 531 PITPNC1 Phosphatidylinositol transfer protein, 1.741 NM_012417 532 cytoplasmic 1 RAB40B RAB40B, member RAS oncogene family 1.74 NM_006822 533 ICAM4 Intercellular adhesion molecule 4, 1.738 NM_001544 534 Landsteiner-Wiener blood group FXYD3 FXYD domain containing ion transport 1.736 NM_005971 535 regulator 3 SPSB1 SPRY domain-containing SOCS box 1.735 NM_025106 536 protein SSB-1 GCH1 GTP cyclohydrolase 1 (dopa-responsive 1.734 NM_000161 537 dystonia) SEQ_ID_#538 IL3-CT0674-060401-492-F11 CT0674 1.734 BG960486 538 Homo sapiens cDNA, mRNA sequence. MELK Maternal embryonic leucine zipper kinase 1.731 NM_014791 539 KIAA1404 KIAA1404 protein 1.731 NM_021035 540 SYNPO Synaptopodin 1.73 NM_007286 541 MAN2B1 Mannosidase, alpha, class 2B, member 1 1.729 NM_000528 542 MAOA Monoamine oxidase A 1.729 NM_000240 543 CCR3 Chemokine (C-C motif) receptor 3 1.729 NM_001837 544 APBA3 Amyloid beta (A4) precursor protein- 1.727 NM_004886 545 binding, family A, member 3 (X11-like 2) OASL 2′-5′-oligoadenylate synthetase-like 1.726 NM_003733 546 PAFAH1B3 Platelet-activating factor acetylhydrolase, 1.726 NM_002573 547 isoform Ib, gamma subunit 29 kDa ARHGAP18 Rho GTPase activating protein 18 1.725 NM_033515 548 MGC13098 Hypothetical protein MGC13098 1.723 BX537878 549 ARHGAP9 Rho GTPase activating protein 9 1.722 NM_032496 550 INSIG1 Insulin induced gene 1 1.721 NM_005542 551 ADORA3 Adenosine A3 receptor 1.72 NM_000677 552 VWF Von Willebrand factor 1.717 NM_000552 553 AGTRAP Angiotensin II receptor-associated protein 1.716 NM_020350 554 ITGAE Integrin, alpha E (antigen CD103, human 1.715 NM_002208 555 mucosal lymphocyte antigen 1; alpha polypeptide) SMAD1 SMAD, mothers against DPP homolog 1 1.715 NM_001003688 556 (Drosophila) RHBDL7 Rhomboid, veinlet-like 7 (Drosophila) 1.713 NM_020684 557 HLA-F Major histocompatibility complex, class I, F 1.713 NM_018950 558 DTX3L Deltex 3-like (Drosophila) 1.711 NM_138287 559 SDK1 Sidekick homolog 1 (chicken) 1.708 NM_152744 560 LCK Lymphocyte-specific protein tyrosine 1.708 NM_005356 561 kinase CBLC Cas-Br-M (murine) ecotropic retroviral 1.707 NM_012116 562 transforming sequence c SEQ_ID_#563 601344760F1 NIH_MGC_8 Homo sapiens 1.706 BE562274 563 cDNA clone IMAGE: 3677607 5′, mRNA sequence. CHST7 Carbohydrate (N-acetylglucosamine 6-O) 1.706 NM_019886 564 sulfotransferase 7 CDCA2 Cell division cycle associated 2 1.706 NM_152562 565 ACOT9 1.706 NM_001033583 566 TYMS Thymidylate synthetase 1.705 NM_001071 567 HCA112 Hepatocellular carcinoma-associated 1.705 NM_018487 568 antigen 112 EVER2 Epidermodysplasia verruciformis 2 1.7 NM_152468 569 LAYN Layilin 1.7 NM_178834 570 MGC7036 Hypothetical protein MGC7036 1.699 NM_145058 571 FLJ11029 Hypothetical protein FLJ11029 1.699 NM_018304 572 FLJ10996 synonym: MGC13033; Homo sapiens 1.696 NM_031447 573 hypothetical protein FLJ10996 (FLJ10996), mRNA. SEQ_ID_#574 Transcribed locus 1.695 BQ010979 574 CENPF Centromere protein F, 350/400ka 1.693 NM_016343 575 (mitosin) BTN3A2 Butyrophilin, subfamily 3, member A2 1.692 NM_007047 576 GAS2L3 Growth arrest-specific 2 like 3 1.692 NM_174942 577 KRT19 Keratin 19 1.69 NM_002276 578 HLA-C Major histocompatibility complex, class I, C 1.689 NM_002117 579 ATP11A ATPase, Class VI, type 11A 1.688 NM_015205 580 SEQ_ID_#581 Transcribed locus, weakly similar to 1.688 BI820139 581 NP_009083.1 zinc finger protein 195 [Homo sapiens ] SEMA4C Sema domain, immunoglobulin domain 1.688 NM_017789 582 (Ig), transmembrane domain (TM) and short cytoplasmic domain, (semaphorin) 4C CCNB1 Cyclin B1 1.685 NM_031966 583 CLDN4 Claudin 4 1.684 NM_001305 584 CCM2 Cerebral cavernous malformation 2 1.683 NM_001029835 585 UBE2C Ubiquitin-conjugating enzyme E2C 1.682 NM_007019 586 FAM3C Family with sequence similarity 3, 1.681 NM_014888 587 member C SERTAD4 SERTA domain containing 4 1.681 NM_019605 588 ELF3 E74-like factor 3 (ets domain 1.68 NM_004433 589 transcription factor, epithelial-specific) FCGRT Fc fragment of IgG, receptor, transporter, 1.678 NM_004107 590 alpha LOC55831 30 kDa protein 1.677 NM_018447 591 APOBEC3C Apolipoprotein B mRNA editing enzyme, 1.676 NM_014508 592 catalytic polypeptide-like 3C FAS Fas (TNF receptor superfamily, member 1.676 NM_000043 593 6) RDH10 Retinol dehydrogenase 10 (all-trans) 1.675 NM_172037 594 LOC440836 Endothelial cell growth factor 1 (platelet- 1.675 NM_001014440 595 derived) TRIM47 Tripartite motif-containing 47 1.675 NM_033452 596 SEQ_ID_#597 T-cell receptor V beta gene segment V- 1.674 BC035390 597 beta-6, clone IGRb11 SEQ_ID_#598 Transcribed locus 1.673 BX114460 598 9-Sep Septin 9 1.672 NM_006640 599 DHFR Dihydrofolate reductase 1.671 NM_000791 600 SLC39A1 Solute carrier family 39 (zinc 1.67 NM_014437 601 transporter), member 1 ARHGAP21 Rho GTPase activating protein 21 1.669 NM_020824 602 FBLN1 Fibulin 1 1.668 NM_001996 603 FOXM1 Forkhead box M1 1.668 NM_021953 604 MGC14289 Similar to RIKEN cDNA 1200014N16 gene 1.666 NM_080660 605 SEQ_ID_#606 UI-E-EJ0-aik-f-24-0-UI.s1 UI-E-EJ0 Homo 1.666 BM681765 606 sapiens cDNA clone UI-E-EJ0-aik-f-24-0- UI 3′, mRNA sequence. ROBO1 Roundabout, axon guidance receptor, 1.666 NM_002941 607 homolog 1 (Drosophila) ADAM12 A disintegrin and metalloproteinase 1.665 NM_003474 608 domain 12 (meltrin alpha) BDNF Brain-derived neurotrophic factor 1.664 NM_001709 609 opposite strand RPS8 Ribosomal protein S8 1.663 NM_001012 610 P2RY2 Purinergic receptor P2Y, G-protein 1.661 NM_002564 611 coupled, 2 C9orf55 Chromosome 9 open reading frame 55 1.661 NM_017925 612 IKBKE Inhibitor of kappa light polypeptide gene 1.661 NM_014002 613 enhancer in B-cells, kinase epsilon RARA Retinoic acid receptor, alpha 1.661 NM_000964 614 ST6GALNAC2 ST6 (alpha-N-acetyl-neuraminyl-2,3- 1.66 NM_006456 615 beta-galactosyl-1,3)-N- acetylgalactosaminide alpha-2,6- sialyltransferase 2 NDUFS7 NADH dehydrogenase (ubiquinone) Fe—S 1.659 NM_024407 616 protein 7, 20 kDa (NADH-coenzyme Q reductase) LAT Linker for activation of T cells 1.659 NM_001014987 617 FLOT1 Flotillin 1 1.658 NM_005803 618 MSMB Microseminoprotein, beta- 1.657 NM_002443 619 TRIM11 Tripartite motif-containing 11 1.653 NM_145214 620 SIPA1L1 Signal-induced proliferation-associated 1 1.653 NM_015556 621 like 1 TRAF4 TNF receptor-associated factor 4 1.652 NM_004295 622 FLJ33860 RP5-1017F8.1; go_function: receptor 1.652 NM_173644 623 activity [goid 0004872] [evidence IEA]; Homo sapiens hypothetical protein FLJ33860 (FLJ33860), mRNA. WBSCR17 Williams-Beuren syndrome chromosome 1.651 NM_022479 624 region 17 RNASEH2A Ribonuclease H2, large subunit 1.65 NM_006397 625 BPNT1 3′(2′),5′-bisphosphate nucleotidase 1 1.649 NM_006085 626 CD3D CD3D antigen, delta polypeptide (TiT3 1.649 NM_000732 627 complex) GBP5 Guanylate binding protein 5 1.647 NM_052942 628 RNF19 Ring finger protein 19 1.646 NM_015435 629 SEQ_ID_#630 Transcribed locus, moderately similar to 1.642 BF037662 630 XP_508230.1 PREDICTED: zinc finger protein 195 [Pan troglodytes] DAPK2 Death-associated protein kinase 2 1.641 NM_014326 631 CCNB2 Glutamate decarboxylase 1 (GAD 1) 1.641 NM_004701 632 FNTB Farnesyltransferase, CAAX box, beta 1.64 NM_002028 633 C16orf7 Chromosome 16 open reading frame 7 1.64 NM_004913 634 NR4A2 Nuclear receptor subfamily 4, group A, 1.637 NM_006186 635 member 2 PITRM1 Pitrilysin metalloproteinase 1 1.636 NM_014889 636 DOCK7 Dedicator of cytokinesis 7 1.636 BG546677 637 JDP2 Jun dimerization protein 2 1.635 NM_130469 638 SEQ_ID_#639 601344760F1 NIH_MGC_8 Homo sapiens 1.635 BE562274 639 cDNA clone IMAGE: 3677607 5′, mRNA sequence. EAP30 EAP30 subunit of ELL complex 1.635 NM_007241 640 DAF Decay accelerating factor for complement 1.634 NM_000574 641 (CD55, Cromer blood group system) CUEDC2 CUE domain containing 2 1.633 NM_024040 642 PLAU Plasminogen activator, urokinase 1.633 NM_002658 643 HDAC9 Histone deacetylase 9 1.632 NM_014707 644 PTCH Patched homolog (Drosophila) 1.632 NM_000264 645 TNFRSF25 Tumor necrosis factor receptor 1.631 NM_003790 646 superfamily, member 25 TK1 Thymidine kinase 1, soluble 1.628 NM_003258 647 FLJ11286 Hypothetical protein FLJ11286 1.628 NM_018381 648 CDCA5 Cell division cycle associated 5 1.628 NM_080668 649 SEMA3B Sema domain, immunoglobulin domain 1.627 NM_004636 650 (Ig), short basic domain, secreted, (semaphorin) 3B PCSK6 Proprotein convertase subtilisin/kexin 1.627 NM_002570 651 type 6 C8orf72 Hypothetical protein MGC39325 1.626 NM_147189 652 STARD5 START domain containing 5 1.626 NM_030574 653 JUB Jub, ajuba homolog (Xenopus laevis) 1.625 NM_032876 654 NAPE-PLD N-acyl-phosphatidylethanolamine- 1.625 NM_198990 655 hydrolyzing phospholipase D HIGD2A Hypothetical protein MGC2198 1.625 NM_138820 656 C1RL Complement component 1, r 1.624 NM_016546 657 subcomponent-like DKFZP564I0422 Hypothetical protein DKFZp564I0422 1.622 NM_031435 658 SCCPDH Saccharopine dehydrogenase (putative) 1.62 NM_016002 659 ZNF503 Zinc finger protein 503 1.616 AK024492 660 PLEKHG3 Pleckstrin homology domain containing, 1.615 AB011171 661 family G (with RhoGef domain) member 3 CD209 CD209 antigen 1.615 NM_021155 662 HLA-A Major histocompatibility complex, class I, A 1.614 NM_002116 663 Cep290 Centrosome protein cep290 1.614 NM_025114 664 KIAA1434 Hypothetical protein KIAA1434 1.612 NM_019593 665 SEQ_ID_#666 Hypothetical LOC389188 1.612 AK097068 666 SEQ_ID_#667 Hypothetical gene supported by 1.612 BX648423 667 AL713721 ARHGAP25 Rho GTPase activating protein 25 1.611 NM_001007231 668 TEP1 Telomerase-associated protein 1 1.61 NM_007110 669 HSC20 J-type co-chaperone HSC20 1.61 NM_172002 670 DLG5 Discs, large homolog 5 (Drosophila) 1.61 NM_004747 671 H6PD Hexose-6-phosphate dehydrogenase 1.61 NM_004285 672 (glucose 1-dehydrogenase) OSBPL3 Oxysterol binding protein-like 3 1.609 NM_015550 673 CDCP1 CUB domain containing protein 1 1.608 NM_022842 674 RCN1 Reticulocalbin 1, EF-hand calcium binding 1.608 NM_002901 675 domain BCL6 B-cell CLL/lymphoma 6 (zinc finger 1.608 NM_001706 676 protein 51) MGAT4B Mannosyl (alpha-1,3-)-glycoprotein beta- 1.607 NM_014275 677 1,4-N-acetylglucosaminyltransferase, isoenzyme B DPEP2 Dipeptidase 2 1.606 NM_022355 678 CLNS1A Chloride channel, nucleotide-sensitive, 1A 1.605 NM_001293 679 DEPDC1 DEP domain containing 1 1.605 NM_017779 680 C10orf54 Cadherin-like 23 1.602 NM_022153 681 SMC2L1 SMC2 structural maintenance of 1.602 NM_006444 682 chromosomes 2-like 1 (yeast) ATG4D APG4 autophagy 4 homolog D (S. cerevisiae) 1.601 NM_032885 683 FAM3B Family with sequence similarity 3, 1.601 NM_058186 684 member B TRADD TNFRSF1A-associated via death domain 1.601 NM_003789 685 GABARAPL1 GABA(A) receptor-associated protein like 1 1.6 NM_031412 686 TGFBI Transforming growth factor, beta- 1.599 NM_000358 687 induced, 68 kDa DAG1 Dystroglycan 1 (dystrophin-associated 1.599 NM_004393 688 glycoprotein 1) TBC1D1 TBC1 (tre-2/USP6, BUB2, cdc16) domain 1.599 NM_015173 689 family, member 1 TCF4 Transcription factor 4 1.597 NM_003199 690 PLXNA1 Plexin A1 1.597 NM_032242 691 CKS2 CDC28 protein kinase regulatory subunit 2 1.597 NM_001827 692 KIAA1295 KIAA1295 1.594 NM_001017995 693 LOC144501 Hypothetical protein LOC144501 1.594 NM_182507 694 MIR16 Membrane interacting protein of RGS16 1.593 NM_016641 695 C7orf19 synonyms: CBCIP2, FLJ12474, FLJ14733; 1.592 NM_025156 696 H_NH0514P08.8; CAP-binding protein complex interacting protein 2; Homo sapiens chromosome 7 open reading frame 19 (C7orf19), mRNA. SLC24A6 Solute carrier family 24 1.592 NM_024959 697 (sodium/potassium/calcium exchanger), member 6 ATP5G2 ATP synthase, H+ transporting, 1.592 NM_001002031 698 mitochondrial F0 complex, subunit c (subunit 9), isoform 2 AMOTL1 Angiomotin like 1 1.59 NM_130847 699 EPAS1 Endothelial PAS domain protein 1 1.59 AK023572 700 ADAM9 A disintegrin and metalloproteinase 1.587 NM_001005845 701 domain 9 (meltrin gamma) HCK Hemopoietic cell kinase 1.586 NM_002110 702 ACOX1 Acyl-Coenzyme A oxidase 1, palmitoyl 1.585 NM_004035 703 SLC25A28 Solute carrier family 25, member 28 1.585 NM_031212 704 DEF6 Differentially expressed in FDCP 6 1.585 NM_022047 705 homolog (mouse) MYH9 Myosin, heavy polypeptide 9, non-muscle 1.584 NM_002473 706 CD300A CD300A antigen 1.584 NM_007261 707 CORO1A Coronin, actin binding protein, 1A 1.583 NM_007074 708 RPS6KA1 Ribosomal protein S6 kinase, 90 kDa, 1.583 NM_001006665 709 polypeptide 1 TRAFD1 TRAF-type zinc finger domain containing 1 1.582 NM_006700 710 NFE2L1 Nuclear factor (erythroid-derived 2)-like 1 1.582 NM_003204 711 SLC35B2 Solute carrier family 35, member B2 1.581 NM_178148 712 ETV7 Ets variant gene 7 (TEL2 oncogene) 1.581 NM_016135 713 KIF2C Kinesin family member 2C 1.58 NM_006845 714 KIAA0999 KIAA0999 protein 1.579 NM_025164 715 NCOA7 Nuclear receptor coactivator 7 1.577 NM_181782 716 IFI16 Interferon, gamma-inducible protein 16 1.577 NM_005531 717 SEQ_ID_#718 AGENCOURT_10444615 NIH_MGC_82 1.576 BU852798 718 Homo sapiens cDNA clone IMAGE: 6619338 5′, mRNA sequence. DTNBP1 Dystrobrevin binding protein 1 1.575 NM_032122 719 CD9 CD9 antigen (p24) 1.574 AK025016 720 AP4B1 Adaptor-related protein complex 4, beta 1 1.574 NM_006594 721 subunit SLC25A23 Solute carrier family 25 (mitochondrial 1.574 NM_024103 722 carrier; phosphate carrier), member 23 CENTD2 Centaurin, delta 2 1.573 NM_015242 723 ATAD2 ATPase family, AAA domain containing 2 1.573 NM_014109 724 SEQ_ID_#725 CDNA FLJ38412 fis, clone FEBRA2009385 1.573 AK095731 725 CIB1 Calcium and integrin binding 1 (calmyrin) 1.573 NM_006384 726 C1orf93 Chromosome 1 open reading frame 93 1.568 NM_152371 727 SEQ_ID_#728 602281279F1 NIH_MGC_86 Homo 1.568 BG109249 728 sapiens cDNA clone IMAGE: 4368955 5′, mRNA sequence. SITPEC Signaling intermediate in Toll pathway, 1.567 NM_016581 729 evolutionarily conserved GUSB Glucuronidase, beta 1.566 NM_000181 730 FLJ10260 Hypothetical protein FLJ10260 1.565 NM_018042 731 FSHPRH1 FSH primary response (LRPR1 homolog, 1.565 NM_006733 732 rat) 1 AURKB Aurora kinase B 1.564 NM_004217 733 USP18 Ubiquitin specific protease 18 1.564 NM_017414 734 PCDH9 Protocadherin 9 1.564 BC008476 735 SFXN3 Sideroflexin 3 1.563 NM_030971 736 TFEB Transcription factor EB 1.562 NM_007162 737 BRRN1 Barren homolog (Drosophila) 1.561 NM_015341 738 HFE Hemochromatosis 1.56 NM_000410 739 NDUFB10 NADH dehydrogenase (ubiquinone) 1 1.56 NM_004548 740 beta subcomplex, 10, 22 kDa FER1L3 Fer-1-like 3, myoferlin (C. elegans) 1.559 NM_013451 741 ATP11C ATPase, Class VI, type 11C 1.559 NM_001010986 742 LOC128387 TatD DNase domain containing 3 1.557 XM_375838 743 MGC11242 Hypothetical protein MGC11242 1.556 NM_024320 744 NUDT1 Nudix (nucleoside diphosphate linked 1.556 NM_002452 745 moiety X)-type motif 1 BTG1 B-cell translocation gene 1, anti- 1.556 NM_001731 746 proliferative RBMS2 RNA binding motif, single stranded 1.555 NM_002898 747 interacting protein 2 C9orf91 Chromosome 9 open reading frame 91 1.554 NM_153045 748 C20orf116 Chromosome 20 open reading frame 116 1.553 NM_023935 749 GSDMDC1 Gasdermin domain containing 1 1.553 NM_024736 750 AYTL2 Hypothetical protein FLJ12443 1.552 NM_024830 751 PVRL2 Poliovirus receptor-related 2 (herpesvirus 1.552 NM_002856 752 entry mediator B) DCP2 DCP2 decapping enzyme homolog (S. cerevisiae) 1.55 NM_152624 753 SAV1 Salvador homolog 1 (Drosophila) 1.55 NM_021818 754 CANT1 Calcium activated nucleotidase 1 1.55 NM_138793 755 PLEKHG2 Pleckstrin homology domain containing, 1.549 NM_022835 756 family G (with RhoGef domain) member 2 IRF6 Interferon regulatory factor 6 1.548 NM_006147 757 PDE4D Phosphodiesterase 4D, cAMP-specific 1.547 NM_006203 758 (phosphodiesterase E3 dunce homolog, Drosophila) SEQ_ID_#759 1.547 XM_087056 759 KLK10 Kallikrein 10 1.546 NM_002776 760 GSR Glutathione reductase 1.545 NM_000637 761 SEQ_ID_#762 Transcribed locus, moderately similar to 1.543 BX108121 762 XP_498467.1 PREDICTED: hypothetical protein XP_498467 [Homo sapiens ] CDC45L CDC45 cell division cycle 45-like (S. cerevisiae) 1.543 NM_003504 763 IGSF2 Immunoglobulin superfamily, member 2 1.543 NM_004258 764 MYO1F Myosin IF 1.542 NM_012335 765 ZFYVE16 Zinc finger, FYVE domain containing 16 1.542 NM_014733 766 RAB31 RAB31, member RAS oncogene family 1.541 NM_006868 767 TOMM34 Translocase of outer mitochondrial 1.54 NM_006809 768 membrane 34 SEQ_ID_#769 602977386F1 NIH_MGC_12 Homo 1.539 BI255338 769 sapiens cDNA clone IMAGE: 5122341 5′, mRNA sequence. SEQ_ID_#770 Homo sapiens clone IMAGE: 110987 1.538 AF143866 770 mRNA sequence. KIAA1305 KIAA1305 1.536 XM_370756 771 HIP1R Huntingtin interacting protein-1-related 1.536 NM_003959 772 PRKD2 Protein kinase D2 1.536 NM_016457 773 ACP2 Acid phosphatase 2, lysosomal 1.534 NM_001610 774 COPZ2 Coatomer protein complex, subunit zeta 2 1.533 NM_016429 775 GNG10 DnaJ-like protein 1.533 NM_004125 776 SEQ_ID_#777 Transcribed locus 1.533 BX117393 777 C1orf85 Chromosome 1 open reading frame 85 1.532 NM_144580 778 NTF5 Neurotrophin 5 (neurotrophin 4/5) 1.532 NM_006179 779 KIAA0101 synonyms: L5, NS5ATP9; isoform 2 is 1.531 NM_001029989 780 encoded by transcript variant 2; Homo sapiens KIAA0101 (KIAA0101), transcript variant 2, mRNA. CLOCK Clock homolog (mouse) 1.531 NM_004898 781 SEQ_ID_#782 AGENCOURT_10424058 NIH_MGC_79 1.53 BU929651 782 Homo sapiens cDNA clone IMAGE: 6663644 5′, mRNA sequence. SEQ_ID_#783 601488213F1 NIH_MGC_69 Homo 1.53 BE876649 783 sapiens cDNA clone IMAGE: 3890762 5′, mRNA sequence. KCTD7 Potassium channel tetramerisation 1.529 NM_153033 784 domain containing 7 RANGNRF RAN guanine nucleotide release factor 1.528 NM_016492 785 KIAA1505 KIAA1505 protein 1.528 NM_020879 786 SEQ_ID_#787 UI-H-BI4-apu-h-06-0-UI.s1 1.528 BF512055 787 NCI_CGAP_Sub8 Homo sapiens cDNA clone IMAGE: 3088762 3′, mRNA sequence. MARVELD3 MARVEL domain containing 3 1.528 NM_052858 788 MYOC Myocilin, trabecular meshwork inducible 1.528 BM712946 789 glucocorticoid response CCND3 Cyclin D3 1.526 NM_001760 790 NAT1 N-acetyltransferase 1 (arylamine N- 1.524 NM_000662 791 acetyltransferase) CD97 CD97 antigen 1.524 NM_001025160 792 OCIAD2 OCIA domain containing 2 1.522 NM_001014446 793 PKIA Protein kinase (cAMP-dependent, 1.522 NM_006823 794 catalytic) inhibitor alpha C2 Complement component 2 1.521 NM_000063 795 ACD Adrenocortical dysplasia homolog 1.521 NM_022914 796 (mouse) FAM83E Hypothetical protein FLJ20200 1.521 NM_017708 797 S100P S100 calcium binding protein P 1.52 NM_005980 798 COX5B Cytochrome c oxidase subunit Vb 1.52 NM_001862 799 CCR1 Chemokine (C-C motif) receptor 1 1.52 NM_001295 800 SLC35D2 Solute carrier family 35, member D2 1.518 NM_007001 801 THAP4 THAP domain containing 4 1.518 NM_015963 802 CHEK1 CHK1 checkpoint homolog (S. pombe) 1.517 NM_001274 803 ZNF326 Zinc finger protein 326 1.516 NM_181781 804 HDHD1A Haloacid dehalogenase-like hydrolase 1.515 NM_012080 805 domain containing 1A SEQ_ID_#806 CDNA FLJ31593 fis, clone NT2RI2002481 1.514 AK056155 806 SEQ_ID_#807 UI-H-CO0-asu-e-10-0-UI.s1 1.514 BM988141 807 NCI_CGAP_Sub9 Homo sapiens cDNA clone IMAGE: 5859954 3′, mRNA sequence. SEQ_ID_#808 Transcribed locus 1.513 BM994952 808 WARP Von Willebrand factor A domain 1.513 NM_022834 809 containing 1 FLJ22794 FLJ22794 protein 1.513 NM_022074 810 STAT2 Signal transducer and activator of 1.512 NM_005419 811 transcription 2, 113 kDa SEQ_ID_#812 Homo sapiens, clone IMAGE: 5092955 1.512 BC046188 812 ANKRD10 Ankyrin repeat domain 10 1.512 NM_017664 813 SLC25A29 Solute carrier family 25, member 29 1.511 NM_152333 814 SSBP2 Single-stranded DNA binding protein 2 1.51 BQ027821 815 BCL11B B-cell CLL/lymphoma 11B (zinc finger 1.509 NM_022898 816 protein) ADAR Adenosine deaminase, RNA-specific 1.509 NM_001025107 817 HPCAL1 Hippocalcin-like 1 1.509 NM_002149 818 PDPN Podoplanin 1.509 NM_001006624 819 TAL1 T-cell acute lymphocytic leukemia 1 1.508 NM_003189 820 JAK3 Janus kinase 3 (a protein tyrosine kinase, 1.508 NM_000215 821 leukocyte) ITPK1 Inositol 1,3,4-triphosphate 5/6 kinase 1.508 NM_014216 822 SCYL2 SCY1-like 2 (S. cerevisiae) 1.507 NM_017988 823 BACE2 Beta-site APP-cleaving enzyme 2 1.507 NM_012105 824 LOC203069 Hypothetical protein LOC203069 1.505 XM_114618 825 LOC116238 Hypothetical protein BC014072 1.504 NM_138463 826 MGC4093 Hypothetical protein MGC4093 1.504 NM_030578 827 MGC17624 MGC17624 protein 1.504 BE872965 828 RFX5 Regulatory factor X, 5 (influences HLA 1.503 NM_000449 829 class II expression) GBF1 Golgi-specific brefeldin A resistance factor 1 1.503 NM_004193 830 CPA6 Carboxypeptidase A6 1.502 NM_020361 831 UCK2 Uridine-cytidine kinase 2 1.502 NM_012474 832 PDXK Pyridoxal (pyridoxine, vitamin B6) kinase 1.501 NM_003681 833 PLSCR3 Phospholipid scramblase 3 1.501 NM_020360 834 SFRS5 Splicing factor, arginine/serine-rich 5 0.666 NM_006925 835 LOC115294 Similar to hypothetical protein FLJ10883 0.665 NM_052937 836 PALLD Palladin 0.665 NM_016081 837 EPS8L1 EPS8-like 1 0.665 NM_017729 838 STXBP6 Syntaxin binding protein 6 (amisyn) 0.665 NM_014178 839 SEQ_ID_#840 Full length insert cDNA YI37C01 0.665 BU737911 840 ADIPOR1 Adiponectin receptor 1 0.664 NM_015999 841 GNL3 Guanine nucleotide binding protein-like 3 0.664 NM_014366 842 (nucleolar) C6orf69 Chromosome 6 open reading frame 69 0.663 NM_173562 843 C15orf17 Chromosome 15 open reading frame 17 0.663 NM_020447 844 MGLL Monoglyceride lipase 0.663 AW298662 845 NCE2 NEDD8-conjugating enzyme 0.662 NM_080678 846 PRKCE Protein kinase C, epsilon 0.662 NM_005400 847 SLCO4A1 Solute carrier organic anion transporter 0.662 BC025345 848 family, member 4A1 TTC9 Tetratricopeptide repeat domain 9 0.661 XM_027236 849 GCSH Glycine cleavage system protein H 0.661 NM_004483 850 (aminomethyl carrier) KPNA4 Karyopherin alpha 4 (importin alpha 3) 0.661 NM_002268 851 GALNT14 UDP-N-acetyl-alpha-D- 0.66 NM_024572 852 galactosamine:polypeptide N- acetylgalactosaminyltransferase 14 (GalNAc-T14) PHF16 PHD finger protein 16 0.659 NM_014735 853 TMEM65 Hypothetical protein BC017881 0.658 NM_194291 854 SRPK1 SFRS protein kinase 1 0.656 NM_003137 855 CPNE3 Copine III 0.656 NM_003909 856 RPL18A Ribosomal protein L18a 0.656 NM_000980 857 ZNF253 Zinc finger protein 253 0.656 NM_021047 858 SPATA5L1 Spermatogenesis associated 5-like 1 0.656 NM_024063 859 SF3B3 Splicing factor 3b, subunit 3, 130 kDa 0.655 NM_012426 860 PFN1 Profilin 1 0.655 NM_005022 861 ODZ4 Odz, odd Oz/ten-m homolog 4 0.654 XM_166254 862 (Drosophila) MOSC1 MOCO sulphurase C-terminal domain 0.653 NM_022746 863 containing 1 LOC400027 Hypothetical gene supported by 0.653 BC047417 864 BC047417 BRAF V-raf murine sarcoma viral oncogene 0.653 NM_004333 865 homolog B1 CEBPG CCAAT/enhancer binding protein (C/EBP), 0.653 NM_001806 866 gamma JMJD1C Jumonji domain containing 1C 0.653 NM_004241 867 MAFF V-maf musculoaponeurotic fibrosarcoma 0.653 NM_012323 868 oncogene homolog F (avian) FEM1C Fem-1 homolog c (C. elegans) 0.653 NM_020177 869 EP300 E1A binding protein p300 0.652 BC040700 870 ZNF505 Zinc finger protein 505 0.652 NM_031218 871 KIAA1001 Arylsulfatase G 0.652 NM_014960 872 SMAP1 Stromal membrane-associated protein 1 0.652 NM_021940 873 C20orf161 Chromosome 20 open reading frame 161 0.652 NM_033421 874 FLJ10726 Hypothetical protein FLJ10726 0.652 NM_018195 875 MGC52423 Hypothetical protein MGC52423 0.652 NM_182517 876 FLJ10156 Family with sequence similarity 64, 0.651 NM_019013 877 member A RECQL5 RecQ protein-like 5 0.651 NM_004259 878 DUSP16 Dual specificity phosphatase 16 0.651 NM_030640 879 SLC7A11 Solute carrier family 7, (cationic amino 0.651 NM_014331 880 acid transporter, y+ system) member 11 HMGCS1 3-hydroxy-3-methylglutaryl-Coenzyme A 0.65 NM_002130 881 synthase 1 (soluble) PPP2R2C Protein phosphatase 2 (formerly 2A), 0.65 NM_020416 882 regulatory subunit B (PR 52), gamma isoform CYB561 Cytochrome b-561 0.649 NM_001017916 883 CDK5R1 Cyclin-dependent kinase 5, regulatory 0.648 NM_003885 884 subunit 1 (p35) MRC2 Mannose receptor, C type 2 0.648 NM_006039 885 TUBB6 Tubulin, beta 6 0.648 NM_032525 886 TNFRSF11A Tumor necrosis factor receptor 0.647 NM_003839 887 superfamily, member 11a, NFKB activator SEC24C SEC24 related gene family, member C (S. cerevisiae) 0.647 NM_004922 888 EIF4EBP2 Eukaryotic translation initiation factor 4E 0.646 NM_004096 889 binding protein 2 CPT1A Carnitine palmitoyltransferase 1A (liver) 0.646 NM_001876 890 OXSR1 Oxidative-stress responsive 1 0.646 NM_005109 891 NPEPPS Aminopeptidase puromycin sensitive 0.646 NM_006310 892 BTBD7 BTB (POZ) domain containing 7 0.645 NM_018167 893 EXTL2 0.645 NM_001033025 894 LOC401152 HCV F-transactivated protein 1 0.645 NM_001001701 895 MAP4K4 Mitogen-activated protein kinase kinase 0.644 NM_004834 896 kinase kinase 4 PCDH21 Protocadherin 21 0.644 NM_033100 897 EYA3 Eyes absent homolog 3 (Drosophila) 0.644 NM_001990 898 GRHL1 Grainyhead-like 1 (Drosophila) 0.644 NM_014552 899 SORT1 Sortilin 1 0.643 NM_002959 900 SEQ_ID_#901 602540462F1 NIH_MGC_59 Homo 0.643 BG495068 901 sapiens cDNA clone IMAGE: 4671519 5′, mRNA sequence. MALL BENE protein 0.643 NM_005434 902 WWTR1 WW domain containing transcription 0.641 NM_015472 903 regulator 1 MAPK14 Mitogen-activated protein kinase 14 0.641 NM_001315 904 KIAA1128 KIAA1128 0.641 NM_018999 905 SEQ_ID_#906 Clone IMAGE: 1257951, mRNA sequence 0.64 BM664056 906 MAP3K9 Mitogen-activated protein kinase kinase 0.64 AK123430 907 kinase 9 MLLT4 Myeloid/lymphoid or mixed-lineage 0.64 NM_005936 908 leukemia (trithorax homolog, Drosophila); translocated to, 4 SEQ_ID_#909 Similar to ankyrin repeat domain 20A 0.639 BC016022 909 KIAA0892; synonym: MGC75361; go_function: 0.638 XM_048457 910 MGC75361 binding [goid 0005488] [evidence IEA]; Homo sapiens KIAA0892 (KIAA0892), mRNA. MFSD1 Major facilitator superfamily domain 0.638 NM_022736 911 containing 1 CPEB2 Cytoplasmic polyadenylation element 0.638 NM_182485 912 binding protein 2 FOSL2 FOS-like antigen 2 0.638 NM_005253 913 NFIB Nuclear factor I/B 0.638 NM_005596 914 SEQ_ID_#915 602068385F1 NIH_MGC_58 Homo 0.638 BF542107 915 sapiens cDNA clone IMAGE: 4067421 5′, mRNA sequence. CREG1 Cellular repressor of E1A-stimulated 0.637 NM_003851 916 genes 1 SEQ_ID_#917 Clone IMAGE: 110436 mRNA sequence 0.637 BU622887 917 TMED10 Transmembrane trafficking protein 0.637 NM_006827 918 KIAA0182 KIAA0182 protein 0.637 NM_014615 919 P53AIP1 P53-regulated apoptosis-inducing protein 1 0.637 NM_022112 920 FTHP1 Ferritin, heavy polypeptide pseudogene 1 0.636 J04755 921 SLC6A15 Solute carrier family 6, member 15 0.635 NM_182767 922 GCKR Glucokinase (hexokinase 4) regulator 0.634 NM_001486 923 SAMD9 Sterile alpha motif domain containing 9 0.634 NM_017654 924 C2orf4 Chromosome 2 open reading frame 4 0.634 NM_015955 925 FLJ10826 0.633 NM_001031707 926 FLJ25952 Zinc finger, DHHC-type containing 20 0.633 NM_153251 927 RFFL Rififylin 0.633 NM_001017368 928 BAIAP2L1 BAI1-associated protein 2-like 1 0.633 NM_018842 929 LOC286052 Homo sapiens cDNA FLJ37785 fis, clone 0.632 AK095104 930 BRHIP2028330. ANKRD15 Ankyrin repeat domain 15 0.632 NM_015158 931 KA36 Type I hair keratin KA36 0.632 NM_182497 932 CKAP4 Cytoskeleton-associated protein 4 0.632 NM_006825 933 13CDNA73 Hypothetical protein CG003 0.632 NM_023037 934 EPS15L1 Epidermal growth factor receptor pathway 0.632 NM_021235 935 substrate 15-like 1 CYP2C9 Cytochrome P450, family 2, subfamily C, 0.632 NM_000771 936 polypeptide 9 ADAMTS17 A disintegrin-like and metalloprotease 0.631 AK057529 937 (reprolysin type) with thrombospondin type 1 motif, 17 SCEL Sciellin 0.631 NM_003843 938 PDK1 Pyruvate dehydrogenase kinase, 0.631 NM_002610 939 isoenzyme 1 FBXL10 F-box and leucine-rich repeat protein 10 0.631 NM_001005366 940 ZNF539 Zinc finger protein 254 0.631 NM_203282 941 CES1 Carboxylesterase 1 0.631 NM_016280 942 (monocyte/macrophage serine esterase 1) SEQ_ID_#943 Homo sapiens cDNA FLJ36869 fis, clone 0.631 AK094188 943 ASTRO2016819. HOOK1 Hook homolog 1 (Drosophila) 0.63 NM_015888 944 CLCN3 Chloride channel 3 0.63 NM_001829 945 SGPL1 Sphingosine-1-phosphate lyase 1 0.63 NM_003901 946 CXCL14 Chemokine (C—X—C motif) ligand 14 0.629 NM_004887 947 SEQ_ID_#948 CDNA FLJ20486 fis, clone KAT08039 0.629 AK000493 948 DIO2 Deiodinase, iodothyronine, type II 0.629 NM_000793 949 PRLR Prolactin receptor 0.628 NM_000949 950 RANBP9 RAN binding protein 9 0.628 NM_005493 951 TSPAN12 Tetraspanin 12 0.628 NM_012338 952 SEQ_ID_#953 Transcribed locus, weakly similar to 0.627 BM987621 953 XP_428540.1 PREDICTED: similar to putative 40S ribosomal protein 20S protein, partial [Gallus gallus] LOC286170 Hypothetical protein LOC286170 0.627 AK055620 954 C3orf4 Chromosome 3 open reading frame 4 0.627 NM_019895 955 QSCN6 Quiescin Q6 0.627 NM_002826 956 KCTD6 Potassium channel tetramerisation 0.627 NM_153331 957 domain containing 6 MAPT Microtubule-associated protein tau 0.626 NM_005910 958 MAP1LC3A Microtubule-associated protein 1 light 0.625 NM_032514 959 chain 3 alpha IFRD1 Interferon-related developmental 0.625 NM_001007245 960 regulator 1 ARHGEF4 Rho guanine nucleotide exchange factor 0.625 NM_015320 961 (GEF) 4 TIGA1 TIGA1 0.624 NM_053000 962 ZBTB5 Zinc finger and BTB domain containing 5 0.624 NM_014872 963 C20orf22 Chromosome 20 open reading frame 22 0.624 NM_015600 964 LOC400451 Hypothetical gene supported by 0.623 NM_207446 965 AK075564; BC060873 PTPN21 Protein tyrosine phosphatase, non- 0.622 NM_007039 966 receptor type 21 SH3BP5 SH3-domain binding protein 5 (BTK- 0.622 NM_001018009 967 associated) FLJ32028 Hypothetical protein FLJ32028 0.622 NM_152680 968 ABCC1 ATP-binding cassette, sub-family C 0.622 NM_004996 969 (CFTR/MRP), member 1 LOC196264 Hypothetical protein LOC196264 0.621 NM_198275 970 BSPRY B-box and SPRY domain containing 0.621 NM_017688 971 PRDM1 PR domain containing 1, with ZNF domain 0.621 NM_001198 972 GAS7 Growth arrest-specific 7 0.621 NM_003644 973 TAX1BP1 Tax1 (human T-cell leukemia virus type I) 0.621 NM_006024 974 binding protein 1 HIPK3 Homeodomain interacting protein kinase 3 0.621 NM_005734 975 TUBA1 Tubulin, alpha 1 (testis specific) 0.621 NM_006000 976 PIGN Phosphatidylinositol glycan, class N 0.62 NM_012327 977 SEQ_ID_#978 CDNA: FLJ22256 fis, clone HRC02860 0.62 AK025909 978 SERPINB1 Serine (or cysteine) proteinase inhibitor, 0.62 NM_030666 979 clade B (ovalbumin), member 1 BCL2L10 BCL2-like 10 (apoptosis facilitator) 0.62 NM_020396 980 PLAGL1 Pleiomorphic adenoma gene-like 1 0.62 NM_006718 981 MAPK13 Mitogen-activated protein kinase 13 0.619 NM_002754 982 PSCA Prostate stem cell antigen 0.619 NM_005672 983 DOCK9 Dedicator of cytokinesis 9 0.618 NM_015296 984 M6PRBP1 Mannose-6-phosphate receptor binding 0.618 NM_005817 985 protein 1 CCNG2 Cyclin G2 0.617 NM_004354 986 BNC2 Basonuclin 2 0.617 BX641030 987 OSBPL10 Oxysterol binding protein-like 10 0.616 NM_017784 988 SEQ_ID_#989 CDNA FLJ41623 fis, clone CTONG3009227 0.616 AK123617 989 PTK6 PTK6 protein tyrosine kinase 6 0.615 NM_005975 990 MGC13159 Hypothetical protein MGC13159 0.615 NM_032927 991 KNS2 Kinesin 2 60/70 kDa 0.615 NM_005552 992 BNIPL BCL2/adenovirus E1B 19 kD interacting 0.615 NM_138278 993 protein like OCA2 Oculocutaneous albinism II (pink-eye 0.614 NM_000275 994 dilution homolog, mouse) TRPC1 Transient receptor potential cation 0.614 NM_003304 995 channel, subfamily C, member 1 TMEM61 Transmembrane protein 61 0.613 NM_182532 996 MAFB V-maf musculoaponeurotic fibrosarcoma 0.612 NM_005461 997 oncogene homolog B (avian) MTERFD2 MTERF domain containing 2 0.612 NM_182501 998 FBXL16 F-box and leucine-rich repeat protein 16 0.612 NM_153350 999 TAB3 TAK1-binding protein 3 0.612 NM_152787 1000 FLJ32001 Chromosome 1 open reading frame 71 0.612 NM_152609 1001 SEQ_ID_#1002 Homo sapiens, clone IMAGE: 2960615, 0.612 BC033124 1002 mRNA SEQ_ID_#1003 CDNA FLJ41489 fis, clone BRTHA2004582 0.611 AK123483 1003 SEQ_ID_#1004 Similar to RIKEN cDNA 9930021J17 0.611 XM_373035 1004 SEQ_ID_#1005 Full-length cDNA clone CS0DF012YD09 of 0.61 BX460266 1005 Fetal brain of Homo sapiens (human) ABHD6 Abhydrolase domain containing 6 0.609 NM_020676 1006 SMURF1 SMAD specific E3 ubiquitin protein ligase 1 0.609 NM_020429 1007 SNAPC3 Small nuclear RNA activating complex, 0.608 NM_003084 1008 polypeptide 3, 50 kDa AADAT Aminoadipate aminotransferase 0.608 NM_016228 1009 VDP Vesicle docking protein p115 0.607 NM_003715 1010 TOB1 Transducer of ERBB2, 1 0.607 NM_005749 1011 TJP1 Tight junction protein 1 (zona occludens 0.607 NM_003257 1012 1) RHOB Ras homolog gene family, member B 0.607 NM_004040 1013 C1orf128 Chromosome 1 open reading frame 128 0.606 NM_020362 1014 PLD1 Phospholipase D1, phophatidylcholine- 0.606 NM_002662 1015 specific TUBB3 Tubulin, beta 3 0.605 NM_006086 1016 RALA V-ral simian leukemia viral oncogene 0.604 NM_005402 1017 homolog A (ras related) GNAI3 Guanine nucleotide binding protein (G 0.604 NM_006496 1018 protein), alpha inhibiting activity polypeptide 3 CPNE8 Copine VIII 0.603 NM_153634 1019 PPID Peptidylprolyl isomerase D (cyclophilin D) 0.603 NM_005038 1020 HIF1A Hypoxia-inducible factor 1, alpha subunit 0.603 NM_001530 1021 (basic helix-loop-helix transcription factor) RASAL1 RAS protein activator like 1 (GAP1 like) 0.602 NM_004658 1022 RINT-1 Rad50-interacting protein 1 0.602 NM_021930 1023 RHOF Ras homolog gene family, member F (in 0.602 NM_019034 1024 filopodia) MAL Mal, T-cell differentiation protein 0.601 NM_002371 1025 PTDSR Phosphatidylserine receptor 0.601 NM_015167 1026 SC5DL Sterol-C5-desaturase (ERG3 delta-5- 0.6 NM_001024956 1027 desaturase homolog, fungal)-like ANKRD6 Ankyrin repeat domain 6 0.6 NM_014942 1028 UCHL5 Ubiquitin carboxyl-terminal hydrolase L5 0.6 NM_015984 1029 LOC163590 Torsin A interacting protein 2 0.6 NM_145034 1030 C8orf61 0.6 NM_001034061 1031 FHOD3 Formin homology 2 domain containing 3 0.6 NM_025135 1032 NCOA1 Nuclear receptor coactivator 1 0.599 NM_003743 1033 PLA2G12A Phospholipase A2, group XIIA 0.599 NM_030821 1034 ELOVL6 ELOVL family member 6, elongation of 0.599 NM_024090 1035 long chain fatty acids (FEN1/Elo2, SUR4/Elo3-like, yeast) RAB2 RAB2, member RAS oncogene family 0.599 NM_002865 1036 C17orf39 Chromosome 17 open reading frame 39 0.598 NM_024052 1037 FLJ20582 Hypothetical protein FLJ20582 0.598 NM_014106 1038 AOX1 Aldehyde oxidase 1 0.597 NM_001159 1039 MALT1 Mucosa associated lymphoid tissue 0.596 NM_006785 1040 lymphoma translocation gene 1 CSNK1E Casein kinase 1, epsilon 0.595 NM_152221 1041 MTPN Myotrophin 0.595 NM_145808 1042 SLIC1 Selectin ligand interactor cytoplasmic-1 0.594 NM_153337 1043 C20orf133 0.593 NM_001033086 1044 EMP1 Epithelial membrane protein 1 0.593 NM_001423 1045 C1orf58 Chromosome 1 open reading frame 58 0.593 NM_144695 1046 BCOR BCL6 co-repressor 0.593 NM_017745 1047 CA12 Carbonic anhydrase XII 0.592 AK022350 1048 C10orf12 Chromosome 10 open reading frame 12 0.592 NM_015652 1049 ACOX2 Acyl-Coenzyme A oxidase 2, branched 0.592 NM_003500 1050 chain C20orf111 Chromosome 20 open reading frame 111 0.591 NM_016470 1051 RNF11 Ring finger protein 11 0.591 NM_014372 1052 SEQ_ID_#1055 CDNA FLJ39000 fis, clone NT2RI2022468 0.591 BX538337 1053 PAQR5 Progestin and adipoQ receptor family 0.591 NM_017705 1054 member V LATS2 LATS, large tumor suppressor, homolog 2 0.59 NM_014572 1055 (Drosophila) FABP5 Fatty acid binding protein 5 (psoriasis- 0.59 NM_001444 1056 associated) FALZ Fetal Alzheimer antigen 0.589 NM_182641 1057 SEQ_ID_#1058 CDNA clone IMAGE: 4800262 0.589 BC040182 1058 PIM1 Pim-1 oncogene 0.589 NM_002648 1059 SEQ_ID_#1060 MRNA; cDNA DKFZp564O0862 (from 0.589 AL080095 1060 clone DKFZp564O0862) SYNE2 Spectrin repeat containing, nuclear 0.589 NM_015180 1061 envelope 2 COL4A3BP Collagen, type IV, alpha 3 (Goodpasture 0.589 NM_005713 1062 antigen) binding protein ACADL Acyl-Coenzyme A dehydrogenase, long 0.588 NM_001608 1063 chain LOC286297; Hypothetical protein LOC286297 0.588 AK097152 1064 bA251O17.4 SEQ_ID_#1065 0.588 NM_032835 1065 TM4SF13 Tetraspanin 13 0.588 NM_014399 1066 NSE1 NSE1 0.588 NM_145175 1067 KIF1B Kinesin family member 1B 0.587 NM_015074 1068 SEQ_ID_#1069 0.587 BC036262 1069 RAP1GDS1 RAP1, GTP-GDP dissociation stimulator 1 0.587 NM_021159 1070 SMCX Smcy homolog, X-linked (mouse) 0.587 NM_004187 1071 KIAA1991 Hypothetical protein KIAA1991 0.586 XM_495886 1072 TYRO3 TYRO3 protein tyrosine kinase 0.586 NM_006293 1073 NFE2L2 Nuclear factor (erythroid-derived 2)-like 2 0.586 NM_006164 1074 SEQ_ID_#1075 603615533F1 NIH_MGC_110 Homo 0.586 BM006561 1075 sapiens cDNA clone IMAGE: 5421225 5′, mRNA sequence. GALNT12 UDP-N-acetyl-alpha-D- 0.586 NM_024642 1076 galactosamine:polypeptide N- acetylgalactosaminyltransferase 12 (GalNAc-T12) CHP Calcium binding protein P22 0.586 NM_007236 1077 SESN2 Sestrin 2 0.586 NM_031459 1078 MGC9913 Hypothetical protein MGC9913 0.585 XM_378178 1079 HTR3B 5-hydroxytryptamine (serotonin) receptor 0.585 NM_006028 1080 3B ACOT11 Thioesterase, adipose associated 0.585 NM_147161 1081 LOC221362 Hypothetical protein LOC221362 0.584 AK091117 1082 SEC14L1 SEC14-like 1 (S. cerevisiae) 0.584 NM_003003 1083 MYOZ1 Myozenin 1 0.584 NM_021245 1084 FBXW11 F-box and WD-40 domain protein 11 0.584 NM_012300 1085 CHMP2B Chromatin modifying protein 2B 0.584 NM_014043 1086 CRYL1 Crystallin, lambda 1 0.583 NM_015974 1087 FLJ10178 Hypothetical protein FLJ10178 0.583 NM_018015 1088 LOC126295 Hypothetical protein LOC126295 0.583 NM_173480 1089 LGMN Legumain 0.583 NM_001008530 1090 MCFD2 Multiple coagulation factor deficiency 2 0.583 NM_139279 1091 GRK4 G protein-coupled receptor kinase 4 0.582 L34408 1092 PGM1 Phosphoglucomutase 1 0.581 NM_002633 1093 FER Fer (fps/fes related) tyrosine kinase 0.581 NM_005246 1094 (phosphoprotein NCP94) ZDHHC21 Zinc finger, DHHC-type containing 21 0.581 NM_178566 1095 DOCK3 Dedicator of cytokinesis 3 0.58 NM_004947 1096 PI4KII Phosphatidylinositol 4-kinase type II 0.58 NM_018425 1097 RUSC2 RUN and SH3 domain containing 2 0.58 NM_014806 1098 SEQ_ID_#1099 CDNA FLJ35001 fis, clone OCBBF2011887 0.579 AK123847 1099 WDFY3 WD repeat and FYVE domain containing 3 0.578 NM_014991 1100 TRERF1 Transcriptional regulating factor 1 0.578 NM_033502 1101 NAGK N-acetylglucosamine kinase 0.578 NM_017567 1102 RBM25; S164; Homo sapiens mRNA; cDNA 0.578 AL832314 1103 RNPC7 DKFZp667O2119 (from clone DKFZp667O2119). FAM62B Family with sequence similarity 62 (C2 0.577 NM_020728 1104 domain containing) member B ANKH Ankylosis, progressive homolog (mouse) 0.577 NM_054027 1105 SEQ_ID_#1106 0.576 XM_379938 1106 SLC13A4 Solute carrier family 13 (sodium/sulfate 0.576 NM_012450 1107 symporters), member 4 CDS1 CDP-diacylglycerol synthase 0.576 NM_001263 1108 (phosphatidate cytidylyltransferase) 1 KDELR3 KDEL (Lys-Asp-Glu-Leu) endoplasmic 0.576 NM_006855 1109 reticulum protein retention receptor 3 HIPK2 synonym: PRO0593; homeodomain- 0.575 NM_014075 1110 interacting protein kinase 2; go_component: cytoplasm [goid 0005737] [evidence ISS]; go_component: nucleus [goid 0005634] [evidence IDA] [pmid 12220523]; go_component: nuclear body [goid 0016604] [evidence TAS] [pmid 14626429]; go_function: ATP binding [goid 0005524] [evidence IEA]; go_function: virion binding [goid 0046790] [evidence IPI] [pmid 14990717]; go_function: protein binding [goid 0005515] [evidence IPI] [pmid 12220523]; go_function: transferase activity [goid 0016740] [evidence IEA]; go_function: transcription corepressor activity [goid 0003714] [evidence TAS] [pmid 9748262]; go_function: protein serine/threonine kinase activity [goid 0004674] [evidence IEA]; go_process: apoptosis [goid 0006915] [evidence IEA]; go_process: transcription [goid 0006350] [evidence IEA]; go_process: virus-host interaction [goid 0019048] [evidence NAS] [pmid 14990717]; go_process: protein amino acid phosphorylation [goid 0006468] [evidence IEA]; go_process: positive regulation of JNK cascade [goid 0046330] [evidence IMP] [pmid 14678985]; go_process: regulation of transcription, DNA-dependent [goid 0006355] [evidence IEA]; go_process: regulation of progression through cell cycle [goid 0000074] [evidence NAS] [pmid 14990717]; go_process: induction of apoptosis by intracellular signals [goid 0008629] [evidence NAS] [pmid 15122315]; go_process: positive regulation of transforming growth factor beta receptor signaling pathway [goid 0030511] [evidence IMP] [pmid 14678985]; Homo sapiens homeodomain interacting protein kinase 2 (HIPK2), mRNA. PBEF1 Pre-B-cell colony enhancing factor 1 0.575 NM_005746 1111 ZNF117 Zinc finger protein 117 (HPF9) 0.574 NM_015852 1112 CFTR Cystic fibrosis transmembrane 0.574 NM_000492 1113 conductance regulator, ATP-binding cassette (sub-family C, member 7) PER3 Period homolog 3 (Drosophila) 0.573 NM_016831 1114 KRTHA3A Keratin, hair, acidic, 3A 0.573 NM_004138 1115 SGEF Src homology 3 domain-containing 0.573 NM_015595 1116 guanine nucleotide exchange factor ENSA Endosulfine alpha 0.572 NM_207043 1117 WNK4 WNK lysine deficient protein kinase 4 0.572 NM_032387 1118 SLC2A13 Solute carrier family 2 (facilitated glucose 0.572 NM_052885 1119 transporter), member 13 ZZANK1 Mindbomb homolog 2 (Drosophila) 0.572 NM_080875 1120 CYYR1 Cysteine/tyrosine-rich 1 0.572 NM_052954 1121 TRIB3 Tribbles homolog 3 (Drosophila) 0.571 NM_021158 1122 C1orf108 Chromosome 1 open reading frame 108 0.571 NM_024595 1123 SEQ_ID_#1024 0.571 AL031723 1124 RNF24 Ring finger protein 24 0.571 NM_007219 1125 H2BFS H2B histone family, member S 0.571 NM_017445 1126 DKK4 Dickkopf homolog 4 (Xenopus laevis) 0.569 NM_014420 1127 MXI1 MAX interactor 1 0.569 NM_001008541 1128 CABLES1 Cdk5 and Abl enzyme substrate 1 0.569 NM_138375 1129 HECTD1 HECT domain containing 1 0.568 NM_015382 1130 MAF 0.567 NM_001031804 1131 PCGF2 Polycomb group ring finger 2 0.567 BM695150 1132 PLXDC2 Plexin domain containing 2 0.567 AK127644 1133 WDR41 WD repeat domain 41 0.567 NM_018268 1134 TSPYL4 TSPY-like 4 0.566 NM_021648 1135 UPP1 Uridine phosphorylase 1 0.565 NM_003364 1136 TMEM37 Transmembrane protein 37 0.565 NM_183240 1137 FBXW7 F-box and WD-40 domain protein 7 0.565 NM_001013415 1138 (archipelago homolog, Drosophila) RPIB9 Rap2-binding protein 9 0.565 NM_138290 1139 SLC1A3 Solute carrier family 1 (glial high affinity 0.564 NM_004172 1140 glutamate transporter), member 3 FAM3D Family with sequence similarity 3, 0.564 NM_138805 1141 member D TSC22D2 TSC22 domain family, member 2 0.563 NM_014779 1142 DSC1 Desmocollin 1 0.563 NM_004948 1143 SRPX2 Sushi-repeat-containing protein, X-linked 2 0.563 NM_014467 1144 GRB14 Growth factor receptor-bound protein 14 0.563 NM_004490 1145 COBL Cordon-bleu homolog (mouse) 0.563 NM_015198 1146 HIST1H2BF Histone 1, H2bf 0.563 NM_003522 1147 C10orf57 Chromosome 10 open reading frame 57 0.563 NM_025125 1148 SEQ_ID_#1149 Transcribed locus 0.562 BM993105 1149 MELL1 Mel transforming oncogene-like 1 0.562 NM_033467 1150 SHMT1 Serine hydroxymethyltransferase 1 0.562 NM_004169 1151 (soluble) SEQ_ID_#1152 0.562 NM_032751 1152 C14orf78 Chromosome 14 open reading frame 78 0.561 XM_290629 1153 DRCTNNB1A Down-regulated by Ctnnb1, a 0.433 NM_032581 1154 SLC24A3 Solute carrier family 24 0.56 NM_020689 1155 (sodium/potassium/calcium exchanger), member 3 RC3H1 0.56 NM_172071 1156 SEQ_ID_#1157 CDNA: FLJ23573 fis, clone LNG12520 0.559 AK027226 1157 SYAP1 Synapse associated protein 1, SAP47 0.559 NM_032796 1158 homolog (Drosophila) D4S234E DNA segment on chromosome 4 (unique) 0.559 NM_014392 1159 234 expressed sequence SEQ_ID_#1160 602540462F1 NIH_MGC_59 Homo 0.559 BG495068 1160 sapiens cDNA clone IMAGE: 4671519 5′, mRNA sequence. B3GNT5 UDP-GlcNAc: betaGal beta-1,3-N- 0.559 NM_032047 1161 acetylglucosaminyltransferase 5 SCGB2A1 Secretoglobin, family 2A, member 1 0.558 NM_002407 1162 ZNF416 Zinc finger protein 416 0.558 NM_017879 1163 LOC146174 Chromosome 16 open reading frame 52 0.557 NM_173501 1164 TPM4 Tropomyosin 4 0.556 NM_003290 1165 KRTHA2 Keratin, hair, acidic, 2 0.556 NM_002278 1166 CPVL Carboxypeptidase, vitellogenic-like 0.555 NM_019029 1167 GADD45B Growth arrest and DNA-damage- 0.555 NM_015675 1168 inducible, beta SEQ_ID_#1169 BX109361 NCI_CGAP_Lu5 Homo sapiens 0.554 BX109361 1169 cDNA clone IMAGp998B174679; IMAGE: 1908400, mRNA sequence. SLC5A1 Solute carrier family 5 (sodium/glucose 0.554 NM_000343 1170 cotransporter), member 1 HNMT Histamine N-methyltransferase 0.554 NM_001024074 1171 SEQ_ID_#1172 CDNA FLJ31407 fis, clone NT2NE2000137 0.554 AK055969 1172 SNX24 Sorting nexing 24 0.554 NM_014035 1173 CPD Carboxypeptidase D 0.553 NM_001304 1174 SEQ_ID_#1175 Transcribed locus 0.553 BX116062 1175 LOC162993 Hypothetical protein LOC162993 0.553 XM_091914 1176 CUL4B Cullin 4B 0.552 NM_003588 1177 H41 Hypothetical protein H41 0.551 NM_017548 1178 SEQ_ID_#1179 CDNA clone IMAGE: 4830452 0.551 BC034636 1179 SNX14 Sorting nexin 14 0.551 NM_153816 1180 ZNRF1 Zinc and ring finger 1 0.551 NM_032268 1181 AHCY S-adenosylhomocysteine hydrolase 0.551 NM_000687 1182 SEQ_ID_#1183 Transcribed locus, strongly similar to 0.551 BF510602 1183 XP_517083.1 PREDICTED: similar to hypothetical protein MGC13159 [Pan troglodytes] CSTB Cystatin B (stefin B) 0.551 NM_000100 1184 RASAL2 RAS protein activator like 2 0.549 NM_004841 1185 ITPR2 Inositol 1,4,5-triphosphate receptor, type 2 0.548 NM_002223 1186 CORO1C Coronin, actin binding protein, 1C 0.547 NM_014325 1187 IL22RA1 Interleukin 22 receptor, alpha 1 0.546 NM_021258 1188 IMPA2 Inositol(myo)-1(or 4)-monophosphatase 2 0.545 NM_014214 1189 PTN Pleiotrophin (heparin binding growth 0.545 NM_002825 1190 factor 8, neurite growth-promoting factor 1) SEQ_ID_#1191 Transcribed locus 0.545 BX327653 1191 PBX3 Pre-B-cell leukemia transcription factor 3 0.545 NM_006195 1192 ST7L Suppression of tumorigenicity 7 like 0.544 AK128799 1193 FLJ20674 Hypothetical protein FLJ20674 0.544 NM_019086 1194 JARID1B Jumonji, AT rich interactive domain 1B 0.543 NM_006618 1195 (RBP2-like) UNC13B Unc-13 homolog B (C. elegans) 0.543 NM_006377 1196 SEC24A SEC24 related gene family, member A (S. cerevisiae) 0.542 XM_094581 1197 MXD1 MAX dimerization protein 1 0.541 NM_002357 1198 ROR1 Receptor tyrosine kinase-like orphan 0.541 NM_005012 1199 receptor 1 SLC22A15 Solute carrier family 22 (organic cation 0.54 NM_018420 1200 transporter), member 15 GDPD3 0.54 NM_001031718 1201 LOC285671 Ring finger protein 180 0.539 NM_178532 1202 COL21A1 Collagen, type XXI, alpha 1 0.538 NM_030820 1203 SEQ_ID_#1204 602540462F1 NIH_MGC_59 Homo 0.538 BG495068 1204 sapiens cDNA clone IMAGE: 4671519 5′, mRNA sequence. EHBP1 EH domain binding protein 1 0.537 NM_015252 1205 FTH1 Ferritin, heavy polypeptide 1 0.537 NM_002032 1206 LOC159090 Similar to hypothetical protein MGC17347 0.537 NM_145284 1207 COQ6 synonym: CGI-10; isoform a is encoded 0.537 NM_015940 1208 by transcript variant 1; go_function: FAD binding [goid 0050660] [evidence IEA]; go_function: monooxygenase activity [goid 0004497] [evidence IEA]; go_function: ubiquinone biosynthesis monooxygenase activity [goid 0015997] [evidence IEA]; go_process: metabolism [goid 0008152] [evidence IEA]; go_process: electron transport [goid 0006118] [evidence IEA]; go_process: ubiquinone biosynthesis [goid 0006744] [evidence IEA]; go_process: aromatic compound metabolism [goid 0006725] [evidence IEA]; Homo sapiens coenzyme Q6 homolog (yeast) (COQ6), transcript variant 1, mRNA. SEQ_ID_#1209 UI-CF-DU1-adq-o-11-0-UI.s1 UI-CF-DU1 0.537 BM978616 1209 Homo sapiens cDNA clone UI-CF-DU1- adq-o-11-0-UI 3′, mRNA sequence. SFT2D2 SFT2 domain containing 2 0.536 NM_199344 1210 DEGS2 Degenerative spermatocyte homolog 2, 0.536 BE512716 1211 lipid desaturase (Drosophila) ERO1L ERO1-like (S. cerevisiae) 0.536 NM_014584 1212 FLJ32421 Chromosome 1 open reading frame 58 0.535 NM_144695 1213 MTHFD2L Methylenetetrahydrofolate dehydrogenase 0.534 NM_001004346 1214 (NADP+ dependent) 2-like PHC1 Polyhomeotic-like 1 (Drosophila) 0.533 NM_004426 1215 IL13RA1 Interleukin 13 receptor, alpha 1 0.533 NM_001560 1216 MINA MYC induced nuclear antigen 0.533 NM_032778 1217 UBE2H Ubiquitin-conjugating enzyme E2H (UBC8 0.533 NM_003344 1218 homolog, yeast) SEQ_ID_#1219 Homo sapiens, clone IMAGE: 4413555, 0.532 BG034859 1219 mRNA C14orf45 Chromosome 14 open reading frame 45 0.532 NM_025057 1220 ABTB2 Ankyrin repeat and BTB (POZ) domain 0.532 NM_145804 1221 containing 2 SLC35F2 Solute carrier family 35, member F2 0.532 NM_017515 1222 GMPPB GDP-mannose pyrophosphorylase B 0.531 NM_013334 1223 INADL InaD-like (Drosophila) 0.531 NM_170605 1224 ANKRD46 Ankyrin repeat domain 46 0.531 NM_198401 1225 WDR26 WD repeat domain 26 0.531 NM_025160 1226 ZYG11A Zyg-11 homolog A (C. elegans) 0.53 NM_001004339 1227 ELL2 Elongation factor, RNA polymerase II, 2 0.53 NM_012081 1228 ARRDC3 Arrestin domain containing 3 0.53 NM_020801 1229 MBD2 Apoptosis-inducing factor (AIF)-like 0.529 NM_032797 1230 mitochondrion-associated inducer of death VARSL Valyl-tRNA synthetase 2-like 0.529 NM_020442 1231 UBE2E2 Ubiquitin-conjugating enzyme E2E 2 0.529 NM_152653 1232 (UBC 4/5 homolog, yeast) C1orf168 Chromosome 1 open reading frame 168 0.529 NM_001004303 1233 TFCP2L1 Transcription factor CP2-like 1 0.528 NM_014553 1234 LOC284825 Hypothetical protein LOC284825 0.528 AI311303 1235 CAPN5 Calpain 5 0.528 NM_004055 1236 VIT Vitrin 0.528 NM_053276 1237 SEQ_ID_#1238 0.528 NM_032746 1238 DKFZp434C0328 Hypothetical protein DKFZp434C0328 0.528 NM_017577 1239 PLEKHG1 synonyms: FLJ31738, KIAA1209; Homo 0.527 NM_001029884 1240 sapiens pleckstrin homology domain containing, family G (with RhoGef domain) member 1 (PLEKHG1), mRNA. CD207 CD207 antigen, langerin 0.526 NM_015717 1241 NOV Nephroblastoma overexpressed gene 0.526 NM_002514 1242 LRFN5 Leucine rich repeat and fibronectin type 0.526 NM_152447 1243 III domain containing 5 7-Mar Membrane-associated ring finger (C3HC4) 7 0.525 NM_022826 1244 RAB6B RAB6B, member RAS oncogene family 0.524 NM_016577 1245 MYEOV Myeloma overexpressed gene (in a subset 0.524 NM_138768 1246 of t(11; 14) positive multiple myelomas) MDFIC MyoD family inhibitor domain containing 0.524 NM_199072 1247 SLC38A2 Solute carrier family 38, member 2 0.524 NM_018976 1248 SEQ_ID_#1249 Transcribed locus 0.523 BM712901 1249 MRPS10 Mitochondrial ribosomal protein S10 0.523 NM_018141 1250 FLJ13910 Hypothetical protein FLJ13910 0.523 NM_022780 1251 ZNF92 Zinc finger protein 92 (HTF12) 0.521 NM_007139 1252 SEQ_ID_#1253 CDNA FLJ30885 fis, clone FEBRA2004987 0.52 AK055447 1253 ST6GALNAC1 ST6 (alpha-N-acetyl-neuraminyl-2,3- 0.52 NM_018414 1254 beta-galactosyl-1,3)-N- acetylgalactosaminide alpha-2,6- sialyltransferase 1 DSC2 Desmocollin 2 0.518 NM_004949 1255 PNMA1 Paraneoplastic antigen MA1 0.518 NM_006029 1256 MGC40368 Hypothetical protein MGC40368 0.517 NM_152772 1257 PDLIM5 PDZ and LIM domain 5 0.516 NM_001011515 1258 SH3D19 SH3 domain protein D19 0.516 NM_001009555 1259 C1orf181 Hypothetical protein FLJ20729 0.515 NM_017953 1260 LTB4DH Leukotriene B4 12- 0.515 NM_012212 1261 hydroxydehydrogenase WDR5B WD repeat domain 5B 0.514 NM_019069 1262 TSCOT Thymic stromal co-transporter 0.514 NM_033051 1263 C1orf21 Chromosome 1 open reading frame 21 0.514 NM_030806 1264 SLC27A6 Solute carrier family 27 (fatty acid 0.513 NM_001017372 1265 transporter), member 6 FLJ25179 C3 and PZP-like, alpha-2-macroglobulin 0.513 NM_144670 1266 domain containing 9 EGLN1 Egl nine homolog 1 (C. elegans) 0.512 NM_022051 1267 PHTF2 Putative homeodomain transcription 0.511 NM_020432 1268 factor 2 GP1BB Glycoprotein Ib (platelet), beta 0.511 NM_000407 1269 polypeptide BCAR3 Breast cancer anti-estrogen resistance 3 0.51 NM_003567 1270 LNX2 Ligand of numb-protein X 2 0.508 NM_153371 1271 RPL23AP7; Homo sapiens cDNA FLJ30702 fis, clone 0.507 AK055264 1272 RPL23AL1; FCBBF2001001. bA395L14.9 CLEC3B C-type lectin domain family 3, member B 0.507 NM_003278 1273 C18orf9 Chromosome 18 open reading frame 9 0.507 NM_024899 1274 CRTAC1 Cartilage acidic protein 1 0.507 NM_018058 1275 C18orf19 Chromosome 18 open reading frame 19 0.506 NM_152352 1276 CNFN Cornifelin 0.506 NM_032488 1277 HIST2H2BE Histone 2, H2be 0.506 NM_003528 1278 WASL Wiskott-Aldrich syndrome-like 0.506 NM_003941 1279 FLRT2 Fibronectin leucine rich transmembrane 0.505 NM_013231 1280 protein 2 SASH1 SAM and SH3 domain containing 1 0.505 NM_015278 1281 GPSM2 G-protein signalling modulator 2 (AGS3- 0.504 NM_013296 1282 like, C. elegans) PLK2 Polo-like kinase 2 (Drosophila) 0.504 NM_006622 1283 SPRR3 Small proline-rich protein 3 0.504 NM_005416 1284 CAST Calpastatin 0.503 NM_001750 1285 RNMT RNA (guanine-7-) methyltransferase 0.503 NM_003799 1286 K5B Keratin 5b 0.503 NM_173352 1287 TM4SF12 Tetraspanin 12 0.503 NM_012338 1288 RRAGD Ras-related GTP binding D 0.503 NM_021244 1289 MT1F Metallothionein 1F (functional) 0.503 NM_005949 1290 RBM35A 0.502 NM_001034915 1291 LYNX1 Ly6/neurotoxin 1 0.501 NM_023946 1292 HK2 Hexokinase 2 0.5 NM_000189 1293 C8orf48 Hypothetical protein FLJ25402 0.5 NM_001007090 1294 MOSPD1 Motile sperm domain containing 1 0.5 NM_019556 1295 PMAIP1 Phorbol-12-myristate-13-acetate-induced 0.499 NM_021127 1296 protein 1 TRPS1 Trichorhinophalangeal syndrome I 0.499 NM_014112 1297 FLJ14054 Hypothetical protein FLJ14054 0.499 NM_024563 1298 SLITL2 Slit-like 2 (Drosophila) 0.498 NM_138440 1299 CTTNBP2 Cortactin binding protein 2 0.498 NM_033427 1300 UBE2G1 Ubiquitin-conjugating enzyme E2G 1 0.497 NM_003342 1301 (UBC7 homolog, C. elegans) SEQ_ID_#1302 UI-E-EJ1-ajs-c-01-0-UI.r1 UI-E-EJ1 Homo 0.497 BQ185835 1302 sapiens cDNA clone UI-E-EJ1-ajs-c-01-0- UI 5′, mRNA sequence. CDKN2B Cyclin-dependent kinase inhibitor 2B 0.496 NM_004936 1303 (p15, inhibits CDK4) KIAA0232 KIAA0232 gene product 0.496 NM_014743 1304 LRRC20 Leucine rich repeat containing 20 0.495 NM_018205 1305 SOCS6 Suppressor of cytokine signaling 6 0.495 NM_004232 1306 KLK13 Kallikrein 13 0.495 NM_015596 1307 ZDHHC15 Zinc finger, DHHC-type containing 15 0.494 NM_144969 1308 UNC84A Unc-84 homolog A (C. elegans) 0.494 NM_025154 1309 LOC147645 Hypothetical protein LOC147645 0.494 XM_085831 1310 FLJ14011 Zinc finger protein 667 0.494 NM_022103 1311 HIST1H3D Histone 1, H3d 0.493 NM_003530 1312 TIMP2 Tissue inhibitor of metalloproteinase 2 0.492 NM_003255 1313 ETNK2 Ethanolamine kinase 2 0.492 NM_018208 1314 SLC6A1 Solute carrier family 6 (neurotransmitter 0.492 NM_003042 1315 transporter, GABA), member 1 MARCKS Myristoylated alanine-rich protein kinase 0.491 NM_002356 1316 C substrate MRCL3 Myosin regulatory light chain MRCL3 0.489 NM_006471 1317 Gcom1 GRINL1A combined protein 0.488 NM_001018100 1318 C21orf5 Chromosome 21 open reading frame 5 0.488 NM_005128 1319 FUT11 Fucosyltransferase 11 (alpha (1,3) 0.486 NM_173540 1320 fucosyltransferase) CYP2C18 Cytochrome P450, family 2, subfamily C, 0.486 NM_000772 1321 polypeptide 18 CTH Cystathionase (cystathionine gamma- 0.485 NM_001902 1322 lyase) CYP2C9 Cytochrome P450, family 2, subfamily C, 0.485 NM_000771 1323 polypeptide 9 FLJ11151 Hypothetical protein FLJ11151 0.484 NM_018340 1324 LOC387758 Similar to RIKEN cDNA 1110018M03 0.482 NM_203371 1325 KIAA1345 KIAA1345 protein 0.481 XM_106386 1326 GNG12 Guanine nucleotide binding protein (G 0.48 NM_018841 1327 protein), gamma 12 SHRM Shroom 0.48 NM_020859 1328 SEQ_ID_#1329 Transcribed locus 0.48 BG191459 1329 PHACTR2 Phosphatase and actin regulator 2 0.48 NM_014721 1330 USP13 Ubiquitin specific protease 13 0.479 NM_003940 1331 (isopeptidase T-3) CIDEA Cell death-inducing DFFA-like effector a 0.479 NM_001279 1332 ETV1 Ets variant gene 1 0.478 NM_004956 1333 MAP3K4 Mitogen-activated protein kinase kinase 0.476 NM_005922 1334 kinase 4 HIC MyoD family inhibitor domain containing 0.476 NM_199072 1335 LOC96610 Hypothetical protein similar to KIAA0187 0.476 NM_080926 1336 gene product DEGS1 Degenerative spermatocyte homolog 1, 0.475 NM_003676 1337 lipid desaturase (Drosophila) SEQ_ID_#1338 CDNA: FLJ22256 fis, clone HRC02860 0.474 AK025909 1338 HPSE Heparanase 0.473 NM_006665 1339 KCNAB1 Potassium voltage-gated channel, shaker- 0.473 NM_003471 1340 related subfamily, beta member 1 BNIP3L BCL2/adenovirus E1B 19 kDa interacting 0.473 NM_004331 1341 protein 3-like NPR3 Natriuretic peptide receptor C/guanylate 0.473 NM_000908 1342 cyclase C (atrionatriuretic peptide receptor C) LOC388727 Hypothetical LOC388727 0.471 XM_373881 1343 CYP26B1 Cytochrome P450, family 26, subfamily B, 0.471 NM_019885 1344 polypeptide 1 SLC38A4 Solute carrier family 38, member 4 0.47 NM_018018 1345 LNX1 Ligand of numb-protein X 0.47 NM_032622 1346 CFLAR CASP8 and FADD-like apoptosis regulator 0.469 NM_003879 1347 MT1X Metallothionein 1X 0.468 NM_005952 1348 PELI1 Pellino homolog 1 (Drosophila) 0.468 NM_020651 1349 CNKSR3 CNKSR family member 3 0.468 NM_173515 1350 SEQ_ID_#1351 AGENCOURT_7760686 NIH_MGC_92 0.468 BQ421887 1351 Homo sapiens cDNA clone IMAGE: 6016357 5′, mRNA sequence. ITM2A Integral membrane protein 2A 0.467 NM_004867 1352 DGAT2 Diacylglycerol O-acyltransferase homolog 0.467 NM_032564 1353 2 (mouse) DKFZp434N2030 Hypothetical protein DKFZp434N2030 0.466 NM_001009894 1354 WASF3 WAS protein family, member 3 0.466 NM_006646 1355 LOC400960 Hypothetical gene supported by 0.466 AK056822 1356 BC040598 TTC22 Hypothetical protein FLJ20619 0.465 NM_017904 1357 CHI3L1 Chitinase 3-like 1 (cartilage glycoprotein- 0.465 NM_001276 1358 39) RBP7 Retinol binding protein 7, cellular 0.464 NM_052960 1359 EGFL5 EGF-like-domain, multiple 5 0.464 XM_376905 1360 PHLDA1 Pleckstrin homology-like domain, family 0.464 NM_007350 1361 A, member 1 CRIP2 Cysteine-rich protein 2 0.464 NM_001312 1362 MYBBP1A MYB binding protein (P160) 1a 0.464 NM_014520 1363 CPA4 Carboxypeptidase A4 0.462 NM_016352 1364 PTP4A1 Protein tyrosine phosphatase type IVA, 0.462 NM_003463 1365 member 1 RBMS1 RNA binding motif, single stranded 0.461 NM_002897 1366 interacting protein 1 FZD7 Frizzled homolog 7 (Drosophila) 0.461 NM_003507 1367 CLDN17 Claudin 17 0.46 NM_012131 1368 FCER1A Fc fragment of IgE, high affinity I, 0.46 NM_002001 1369 receptor for; alpha polypeptide PDZK8 PDZ domain containing 8 0.459 NM_173791 1370 SPTLC1 Serine palmitoyltransferase, long chain 0.459 NM_178324 1371 base subunit 1 EPB41L4A Erythrocyte membrane protein band 4.1 0.458 NM_022140 1372 like 4A FLJ39501 Cytochrome P450, family 2, subfamily E, 0.458 NM_173483 1373 polypeptide 2 homolog ZNF430 Zinc finger protein 430 0.457 NM_025189 1374 SEQ_ID_#1375 CDNA clone IMAGE: 4838152 0.457 BC034596 1375 AGR2 Anterior gradient 2 homolog (Xenopus 0.456 NM_006408 1376 laevis) RIOK3 RIO kinase 3 (yeast) 0.456 NM_003831 1377 SNX9 Sorting nexin 9 0.456 NM_016224 1378 SEQ_ID_#1379 Transcribed locus, strongly similar to 0.454 AW510697 1379 NP_080835.1 thioredoxin-like 5 [Mus musculus] BCL10 B-cell CLL/lymphoma 10 0.453 NM_003921 1380 AK3 Adenylate kinase 3-like 1 0.453 NM_013410 1381 SEQ_ID_#1382 0.452 NM_014688 1382 CMAS Cytidine monophosphate N- 0.452 NM_018686 1383 acetylneuraminic acid synthetase SEQ_ID_#1384 Transcribed locus 0.451 AI632692 1384 MYO6 Myosin VI 0.45 NM_004999 1385 FLJ31153 Hypothetical protein FLJ31153 0.45 NM_144600 1386 PPP1R2 Protein phosphatase 1, regulatory 0.449 NM_006241 1387 (inhibitor) subunit 2 LPIN1 Lipin 1 0.448 NM_145693 1388 XK Kell blood group precursor (McLeod 0.448 NM_021083 1389 phenotype) ACOT4 Peroxisomal acyl-CoA thioesterase 2B 0.448 NM_152331 1390 CHAC2 Similar to RIKEN cDNA 2510006C20 gene 0.447 NM_001008708 1391 ENC1 Ectodermal-neural cortex (with BTB-like 0.447 NM_003633 1392 domain) UBL3 Ubiquitin-like 3 0.446 NM_007106 1393 ACPP Acid phosphatase, prostate 0.446 NM_001099 1394 SLC7A5 Solute carrier family 7 (cationic amino 0.445 NM_003486 1395 acid transporter, y+ system), member 5 C15orf29 Chromosome 15 open reading frame 29 0.444 NM_024713 1396 WDR37 WD repeat domain 37 0.443 NM_014023 1397 ZNF662 Zinc finger protein 662 0.442 NM_207404 1398 LOC152831 Klotho beta like 0.442 NM_175737 1399 FN5 B-cell CLL/lymphoma 7B 0.441 NM_020179 1400 KIF21A Kinesin family member 21A 0.44 NM_017641 1401 SPIRE1 Spire homolog 1 (Drosophila) 0.44 NM_020148 1402 SLC7A11 Solute carrier family 7, (cationic amino 0.439 NM_014331 1403 acid transporter, y+ system) member 11 TEAD1 TEA domain family member 1 (SV40 0.438 NM_021961 1404 transcriptional enhancer factor) SH3BGRL2 SH3 domain binding glutamic acid-rich 0.437 NM_031469 1405 protein like 2 PDZRN3 PDZ domain containing RING finger 3 0.436 NM_015009 1406 PHGDH Phosphoglycerate dehydrogenase 0.435 NM_006623 1407 CAP2 CAP, adenylate cyclase-associated 0.435 NM_006366 1408 protein, 2 (yeast) PARP11 Poly (ADP-ribose) polymerase family, 0.435 NM_020367 1409 member 11 ALS2CR2 Amyotrophic lateral sclerosis 2 (juvenile) 0.433 NM_018571 1410 chromosome region, candidate 2 LOC168850 Hypothetical protein LOC168850 0.433 NM_176814 1411 SMPDL3A Sphingomyelin phosphodiesterase, acid- 0.433 NM_006714 1412 like 3A C1orf9 Chromosome 1 open reading frame 9 0.432 NM_014283 1413 HLA-DQB2 Major histocompatibility complex, class II, 0.432 NM_182549 1414 DQ beta 2 ZA20D2 Zinc finger, A20 domain containing 2 0.431 NM_006007 1415 SNX16 Sorting nexin 16 0.431 NM_022133 1416 ITCH Itchy homolog E3 ubiquitin protein ligase 0.431 NM_031483 1417 (mouse) MAMDC2 MAM domain containing 2 0.431 NM_153267 1418 BEAN Brain expressed, associated with Nedd4 0.43 XM_375359 1419 ABHD5 Abhydrolase domain containing 5 0.43 NM_016006 1420 AGA Aspartylglucosaminidase 0.429 NM_000027 1421 SPAG1 Sperm associated antigen 1 0.429 NM_003114 1422 BOC Brother of CDO 0.428 NM_033254 1423 MGST1 Microsomal glutathione S-transferase 1 0.428 NM_020300 1424 C5orf13 Chromosome 5 open reading frame 13 0.427 NM_004772 1425 PLEKHA5 Pleckstrin homology domain containing, 0.426 NM_019012 1426 family A member 5 ZNF555 Zinc finger protein 555 0.426 NM_152791 1427 TADA3L Transcriptional adaptor 3 (NGG1 0.425 NM_133480 1428 homolog, yeast)-like PRKACB Protein kinase, cAMP-dependent, 0.424 NM_002731 1429 catalytic, beta HIST1H2BG Histone 1, H2bg 0.424 NM_003518 1430 PALMD Palmdelphin 0.423 NM_017734 1431 LOC136288 Hypothetical protein LOC136288 0.421 XM_059832 1432 CALB2 Calbindin 2, 29 kDa (calretinin) 0.419 NM_001740 1433 PLA2G4A Phospholipase A2, group IVA (cytosolic, 0.417 NM_024420 1434 calcium-dependent) MT1H Metallothionein 1H 0.417 NM_005951 1435 SEQ_ID_#1436 0.417 AL031602 1436 SEQ_ID_#1437 Full-length cDNA clone CS0DD009YB17 of 0.417 AK000776 1437 Neuroblastoma Cot 50-normalized of Homo sapiens (human) PFKFB3 6-phosphofructo-2-kinase/fructose-2,6- 0.415 NM_004566 1438 biphosphatase 3 C10orf45 Chromosome 10 open reading frame 45 0.415 AK096685 1439 BPGM 2,3-bisphosphoglycerate mutase 0.415 NM_001724 1440 EML1 Echinoderm microtubule associated 0.193 NM_001008707 1441 protein like 1 AKR1C1 Aldo-keto reductase family 1, member C1 0.414 NM_001353 1442 (dihydrodiol dehydrogenase 1; 20-alpha (3-alpha)-hydroxysteroid dehydrogenase) TBC1D10 TBC1 domain family, member 10A 0.414 NM_031937 1443 MN1 Meningioma (disrupted in balanced 0.414 NM_002430 1444 translocation) 1 LOC120379 Hypothetical protein BC019238 0.414 NM_138789 1445 IL18 Interleukin 18 (interferon-gamma- 0.414 NM_001562 1446 inducing factor) GSTA4 Glutathione S-transferase A4 0.413 NM_001512 1447 LOC93622 Hypothetical protein BC006130 0.412 NM_138699 1448 TNFRSF19 Tumor necrosis factor receptor 0.412 NM_148957 1449 superfamily, member 19 TMOD3 Tropomodulin 3 (ubiquitous) 0.41 NM_014547 1450 C10orf99 Chromosome 10 open reading frame 99 0.406 NM_207373 1451 ACAA2 Acetyl-Coenzyme A acyltransferase 2 0.404 NM_006111 1452 (mitochondrial 3-oxoacyl-Coenzyme A thiolase) SEQ_ID_#1453 CDNA FLJ39842 fis, clone SPLEN2014293 0.404 AK097161 1453 CNN3 Calponin 3, acidic 0.404 NM_001839 1454 RPESP RPE-spondin 0.403 NM_153225 1455 SLC16A9 Solute carrier family 16 (monocarboxylic 0.402 NM_194298 1456 acid transporters), member 9 FLJ42117 FLJ42117 protein 0.398 NM_198463 1457 SYTL5 Synaptotagmin-like 5 0.398 NM_138780 1458 WNK1 WNK lysine deficient protein kinase 1 0.397 NM_018979 1459 TncRNA Trophoblast-derived noncoding RNA 0.395 AF001893 1460 UACA Uveal autoantigen with coiled-coil 0.395 NM_001008224 1461 domains and ankyrin repeats FRAS1 Fraser syndrome 1 0.394 NM_025074 1462 KLHL24 DRE1 protein 0.393 NM_017644 1463 RFK Riboflavin kinase 0.392 NM_018339 1464 LOC92196 Similar to death-associated protein 0.392 NM_001017920 1465 MT1E Metallothionein 1E (functional) 0.392 NM_175617 1466 AKR1C3 Aldo-keto reductase family 1, member C3 0.392 NM_003739 1467 (3-alpha hydroxysteroid dehydrogenase, type II) RAP2A RAP2A, member of RAS oncogene family 0.39 NM_021033 1468 ZNF76 Zinc finger protein 76 (expressed in 0.389 NM_003427 1469 testis) CHAC1 Hypothetical protein MGC4504 0.389 NM_024111 1470 GATM Glycine amidinotransferase (L- 0.386 NM_001482 1471 arginine:glycine amidinotransferase) NHLH2 Nescient helix loop helix 2 0.386 NM_005599 1472 H-plk Zinc finger protein 117 (HPF9) 0.386 NM_015852 1473 PANK1 Pantothenate kinase 1 0.385 NM_138316 1474 RORA RAR-related orphan receptor A 0.384 NM_002943 1475 AFF4 AF4/FMR2 family, member 4 0.383 NM_014423 1476 MGC39372 Hypothetical protein MGC39372 0.383 XM_376463 1477 TP53INP2 Tumor protein p53 inducible nuclear 0.383 NM_021202 1478 protein 2 GGTA1 Glycoprotein, alpha-galactosyltransferase 1 0.382 AF378123 1479 SEQ_ID_#1480 Transcribed locus 0.381 BI757437 1480 DUSP5 Dual specificity phosphatase 5 0.381 NM_004419 1481 NAP1L2 Nucleosome assembly protein 1-like 2 0.381 NM_021963 1482 HBA2 Hemoglobin, alpha 2 0.38 NM_000517 1483 SEQ_ID_#1484 Homo sapiens, clone IMAGE: 5199401, 0.38 BC027846 1484 mRNA PFN2 Profilin 2 0.38 NM_002628 1485 GPX3 Glutathione peroxidase 3 (plasma) 0.377 NM_002084 1486 SEQ_ID_#1487 CDNA FLJ14188 fis, clone NT2RP2005980 0.376 AK024250 1487 PKIB Protein kinase (cAMP-dependent, 0.373 NM_032471 1488 catalytic) inhibitor beta DHRS1 Dehydrogenase/reductase (SDR family) 0.372 NM_138452 1489 member 1 AMFR Autocrine motility factor receptor 0.371 NM_001144 1490 PDGFRA Platelet-derived growth factor receptor, 0.368 NM_006206 1491 alpha polypeptide TSPAN7 Tetraspanin 7 0.367 NM_004615 1492 ARG2 Arginase, type II 0.367 NM_001172 1493 AMACR Alpha-methylacyl-CoA racemase 0.366 NM_014324 1494 ABLIM1 Actin binding LIM protein 1 0.363 NM_001003407 1495 SEQ_ID_#1496 Full length insert cDNA clone ZD63G05 0.361 AF088051 1496 CEACAM7 Carcinoembryonic antigen-related cell 0.361 NM_006890 1497 adhesion molecule 7 TP53I3 Tumor protein p53 inducible protein 3 0.357 NM_004881 1498 OXR1 Oxidation resistance 1 0.356 NM_181354 1499 NUCB2 Nucleobindin 2 0.356 NM_005013 1500 SEQ_ID_#1501 Transcribed locus 0.356 BF508966 1501 ATP6V1C2 ATPase, H+ transporting, lysosomal 0.356 NM_144583 1502 42 kDa, V1 subunit C isoform 2 C1orf71 Chromosome 1 open reading frame 71 0.355 NM_152609 1503 SEQ_ID_#1504 Transcribed locus 0.354 BI757437 1504 GJA1 Gap junction protein, alpha 1, 43 kDa 0.353 NM_000165 1505 (connexin 43) IGSF11 Immunoglobulin superfamily, member 11 0.353 NM_001015887 1506 PER1 Period homolog 1 (Drosophila) 0.352 NM_002616 1507 C1orf42 Chromosome 1 open reading frame 42 0.351 NM_019060 1508 RGC32 Response gene to complement 32 0.351 NM_014059 1509 A2ML1 C3 and PZP-like, alpha-2-macroglobulin 0.35 NM_144670 1510 domain containing 9 CAB39L Calcium binding protein 39-like 0.35 NM_030925 1511 ASAH3 N-acylsphingosine amidohydrolase 0.348 NM_133492 1512 (alkaline ceramidase) 3 SOSTDC1 Sclerostin domain containing 1 0.346 NM_015464 1513 ABCG2 ATP-binding cassette, sub-family G 0.346 NM_004827 1514 (WHITE), member 2 AADACL2 Arylacetamide deacetylase-like 2 0.346 NM_207365 1515 DPCR1 Diffuse panbronchiolitis critical region 1 0.346 NM_080870 1516 C18orf25 Chromosome 18 open reading frame 25 0.343 NM_001008239 1517 AKR1C2 Aldo-keto reductase family 1, member C2 0.342 NM_001354 1518 (dihydrodiol dehydrogenase 2; bile acid binding protein; 3-alpha hydroxysteroid dehydrogenase, type III) TUBB2A Tubulin, beta 2 0.341 NM_001069 1519 RASGEF1B RasGEF domain family, member 1B 0.341 NM_152545 1520 CST6 Cystatin E/M 0.334 NM_001323 1521 ARHGAP5 synonyms: p190-B, RhoGAPS; isoform a 0.331 NM_001030055 1522 is encoded by transcript variant 1; p105 RhoGAP; Rho GTPase-activating protein; p100 RasGAP-associated p105 protein; go_component: membrane [goid 0016020] [evidence IEA]; go_component: cytoplasm [goid 0005737] [evidence TAS] [pmid 8537347]; go_function: GTPase activity [goid 0003924] [evidence TAS] [pmid 8537347]; go_function: Rho GTPase activator activity [goid 0005100] [evidence TAS] [pmid 8537347]; go_process: cell adhesion [goid 0007155] [evidence TAS] [pmid 8537347]; go_process: Rho protein signal transduction [goid 0007266] [evidence TAS] [pmid 8537347]; Homo sapiens Rho GTPase activating protein 5 (ARHGAP5), transcript variant 1, mRNA. C21orf81 Chromosome 21 open reading frame 81 0.329 NM_153750 1523 CCDC6 Coiled-coil domain containing 6 0.328 NM_005436 1524 ANKRD37 Ankyrin repeat domain 37 0.326 NM_181726 1525 NQO1 NAD(P)H dehydrogenase, quinone 1 0.324 NM_000903 1526 AKR1B10 Aldo-keto reductase family 1, member 0.323 NM_020299 1527 B10 (aldose reductase) ATP6V0A4 ATPase, H+ transporting, lysosomal V0 0.322 NM_020632 1528 subunit a isoform 4 LOC339400 Hypothetical protein LOC339400 0.321 AK056431 1529 GNA14 Guanine nucleotide binding protein (G 0.32 NM_004297 1530 protein), alpha 14 TFAP2B Transcription factor AP-2 beta (activating 0.319 NM_003221 1531 enhancer binding protein 2 beta) C9orf58 Chromosome 9 open reading frame 58 0.318 NM_001002260 1532 RDH12 Retinol dehydrogenase 12 (all-trans and 0.316 NM_152443 1533 9-cis) BLZF1 Basic leucine zipper nuclear factor 1 0.315 NM_003666 1534 (JEM-1) GRPEL2 GrpE-like 2, mitochondrial (E. coli) 0.312 NM_152407 1535 LOC389432 Homo sapiens SAM domain containing 1 0.31 NM_001030060 1536 (LOC389432), mRNA. YOD1 YOD1 OTU deubiquinating enzyme 1 0.309 NM_018566 1537 homolog (yeast) ARG1 Arginase, liver 0.176 NM_000045 1538 KRT6B Keratin 6B 0.309 NM_005555 1539 SDR-O Orphan short-chain dehydrogenase/ 0.301 NM_148897 1540 reductase BEXL1 Brain expressed X-linked-like 1 0.301 XM_043653 1541 FAM43A Family with sequence similarity 43, 0.3 NM_153690 1542 member A IL1F5 Interleukin 1 family, member 5 (delta) 0.295 NM_012275 1543 CITED2 Cbp/p300-interacting transactivator, with 0.295 NM_006079 1544 Glu/Asp-rich carboxy-terminal domain, 2 FLJ10980 Hypothetical protein FLJ10980 0.295 BQ277484 1545 RNASE7 Ribonuclease, RNase A family, 7 0.292 NM_032572 1546 SEQ_ID_#1547 Similar to ankyrin repeat domain 20A 0.292 BC016022 1547 DEPDC6 DEP domain containing 6 0.292 NM_022783 1548 PADI1 Peptidyl arginine deiminase, type I 0.287 NM_013358 1549 SEQ_ID_#1550 Full length insert cDNA clone YI40A07 0.287 AI819863 1550 SPRR2D Small proline-rich protein 2D 0.286 NM_006945 1551 S100A12 S100 calcium binding protein A12 0.286 NM_005621 1552 (calgranulin C) GHR Growth hormone receptor 0.286 NM_000163 1553 SEQ_ID_#1554 Homo sapiens hypothetical LOC441178 0.286 XM_379456 1554 (LOC441178), mRNA. ZDHHC20 Zinc finger, DHHC-type containing 20 0.283 NM_153251 1555 LOC115749 Hypothetical protein LOC115749 0.281 XM_056680 1556 NGEF Neuronal guanine nucleotide exchange 0.279 NM_019850 1557 factor LOC56901 NADH:ubiquinone oxidoreductase MLRQ 0.278 NM_020142 1558 subunit homolog SORBS1 0.277 NM_001034954 1559 HCG22 HLA complex group 22 0.276 XM_496804 1560 FLJ40432 Hypothetical protein FLJ40432 0.275 NM_152523 1561 SBSN Suprabasin 0.274 NM_198538 1562 TNFAIP3 Tumor necrosis factor, alpha-induced 0.273 BG218400 1563 protein 3 ZNF101 Zinc finger protein 101 0.27 NM_033204 1564 ZBED2 Zinc finger, BED-type containing 2 0.269 NM_024508 1565 DDAH1 Dimethylarginine dimethylaminohydrolase 1 0.266 NM_012137 1566 SLC16A6 Solute carrier family 16 (monocarboxylic 0.263 NM_004694 1567 acid transporters), member 6 SH3GL3 SH3-domain GRB2-like 3 0.262 NM_003027 1568 SEQ_ID_#1569 Homo sapiens hypothetical LOC441178 0.259 XM_379456 1569 (LOC441178), mRNA. FNDC4 Fibronectin type III domain containing 4 0.259 NM_022823 1570 PAQR8 Progestin and adipoQ receptor family 0.255 NM_133367 1571 member VIII SEQ_ID_#1572 Similar to ankyrin repeat domain 20A 0.248 AK092114 1572 IL8RB Interleukin 8 receptor, beta 0.244 NM_001557 1573 HIST1H2BC Histone 1, H2bc 0.243 NM_003526 1574 RGS17 Regulator of G-protein signalling 17 0.243 NM_012419 1575 SLURP1 Secreted LY6/PLAUR domain containing 1 0.24 NM_020427 1576 BBOX1 Butyrobetaine (gamma), 2-oxoglutarate 0.238 NM_003986 1577 dioxygenase (gamma-butyrobetaine hydroxylase) 1 EDN3 Endothelin 3 0.229 NM_000114 1578 MT1G Metallothionein 1G 0.228 NM_005950 1579 LOC283824 Hypothetical protein LOC283824 0.227 BX647541 1580 PCSK5 Proprotein convertase subtilisin/kexin 0.225 NM_006200 1581 type 5 SIAT2 ST6 beta-galactosamide alpha-2,6- 0.224 NM_032528 1582 sialyltranferase 2 SYNPO2L Synaptopodin 2-like 0.222 NM_024875 1583 PNLIPRP3 Pancreatic lipase-related protein 3 0.221 NM_001011709 1584 ME1 Malic enzyme 1, NADP(+)-dependent, 0.221 NM_002395 1585 cytosolic TCP11L2 Hypothetical protein MGC40368 0.22 NM_152772 1586 ZNF426 Zinc finger protein 426 0.215 NM_024106 1587 CGNL1 Cingulin-like 1 0.214 NM_032866 1588 MGC11324 Hypothetical protein MGC11324 0.21 NM_032717 1589 LOC401097 Similar to LOC166075 0.207 XM_376281 1590 KRTAP3-2 Keratin associated protein 3-2 0.204 NM_031959 1591 TGM3 Transglutaminase 3 (E polypeptide, 0.203 NM_003245 1592 protein-glutamine-gamma- glutamyltransferase) CRYM Crystallin, mu 0.199 NM_001014444 1593 CTNNAL1 Catenin (cadherin-associated protein), 0.19 NM_003798 1594 alpha-like 1 CRYAB Crystallin, alpha B 0.189 NM_001885 1595 UPK1A Uroplakin 1A 0.169 NM_007000 1596 ECG2 Esophagus cancer-related gene-2 0.166 NM_032566 1597 FLJ21511 Hypothetical protein FLJ21511 0.162 NM_025087 1598 C1orf177 Chromosome 1 open reading frame 177 0.161 NM_152607 1599 SEQ_ID_#1600 Homo sapiens cDNA clone 0.158 BC042588 1600 IMAGE: 4826738. ALOX12 Arachidonate 12-lipoxygenase 0.157 NM_000697 1601 HIG2 Hypoxia-inducible protein 2 0.156 NM_013332 1602 C1orf161 Chromosome 1 open reading frame 161 0.154 NM_152367 1603 SEQ_ID_#1604 0.152 NM_006518 1604 FLG Filaggrin 0.147 NM_002016 1605 SEQ_ID_#1606 Transcribed locus, weakly similar to 0.145 BM994473 1606 XP_220549.3 PREDICTED: similar to Zinc finger protein 287 (Zfp-287) (Zinc finger protein SKAT-2) [Rattus norvegicus] MT1M Metallothionein 1K 0.129 NM_176870 1607 P11 26 serine protease 0.125 NM_006025 1608 NP Nucleoside phosphorylase 0.113 NM_000270 1609 CRISP2 Cysteine-rich secretory protein 2 0.106 NM_003296 1610 ZNF365 Hypothetical protein LOC283045 0.106 NM_014951 1611 CLDN10 Claudin 10 0.0968 NM_006984 1612 CDA Cytidine deaminase 0.0876 NM_001785 1613 EPB41L3 Erythrocyte membrane protein band 4.1- 0.0832 NM_012307 1614 like 3 SFTPG GSGL541 0.0709 NM_205854 1615 SNX19 Sorting nexin 19 0.0664 NM_014758 1616 GYS2 Glycogen synthase 2 (liver) 0.0535 NM_021957 1617 DSG1 Desmoglein 1 0.0405 NM_001942 1618 CRISP3 Cysteine-rich secretory protein 3 0.039 NM_006061 1619 SEQ_ID_#1620 CDNA FLJ43417 fis, clone OCBBF2026025 0.0268 AK125406 1620

These 1620 genes comprised an EE transcript signature, also termed an EE transcriptome. The most induced transcript in EE was eotaxin-3; levels of eotaxin-3 strongly correlated with disease severity.

In one embodiment, the EE transcriptome was used to evaluate EE patients pre- and post-treatment regimens. For example, corticosteroids are frequently administered to patients with EE, and the specific glucocorticoid fluticasone propionate has been shown to induce EE disease remission (Gastroenterology 131 (2006) 1381) and to reverse EE gene dysregulation (J. Allergy Clin. Immunol., 120 (2007) 1292; U.S. Application Ser. No. 61/118,981, filed Dec. 1, 2008), each of which is incorporated by reference herein in its entirety.

As shown in FIG. 6, treatment of EE patients with fluticasone propionate normalized greater than 99% of the EE transcriptome (1605 genes/1620 genes), while leaving less than 1% of the EE transcriptome (13 genes/1620 genes) resistant to fluticasone propionate treatment. This group of 13 non-responsive genes is SEQ ID NOS. 6, 35, 43, 61, 129, 1358, 1441, 1515, 1538, 1584, 1615, 1618, and 1620. Evaluation of these genes provides a marker of past, present, and/or future active disease, especially in the absence of overt disease. These 13 genes were resistant to therapy, however, therapy resulted in normal clinical and/or physical characteristics. Thus, these 13 genes can be used to evaluate a patient's propensity to EE, particularly in the absence of clinical or physical symptoms of EE or microscopic findings typical of EE. Because the profiles of these genes, i.e., whether they were over-expressed or under-expressed, did not change when the patient was on therapy, these 13 genes can be used to evaluate whether a patient had EE in the past or currently has inactive EE. These 13 genes can be used to evaluate EE in an asymptomatic population or when past EE is suspected in a non-active EE individual at the time of endoscopy. In one embodiment, the expression level of at least one of these 13 genes is compared to control levels and under- or over-expression of one or more of these 13 genes by ≧1.5 fold, indicating that the patient is either a past EE patient and/or is susceptible to future EE disease development.

The method may evaluate treatment efficacy with different drugs within a particular group (e.g., different corticosteroids), among the same group (e.g., corticosteroids compared to non-corticosteroids), or among different groups (e.g., steroids compared to non-steroid drugs). The method may evaluate treatment efficacy at different doses, provided in different therapeutic regimens (e.g., frequency, duration, etc.).

Normalization of expression levels of 99% of the genes in the EE transcriptome by fluticasone propionate treatment permitted determination of potential pathways by which fluticasone propionate and other treatments, e.g., other glucocorticoids, treat EE. In one embodiment, the EE transcriptome was used to examine the cellular and molecular pathways of EE, and the way by which a particular therapy treated EE, provided information about the basis, attributes, and potential modifiers of EE. For example, a role of interleukin 13 (IL-13) and its signaling pathways has been implicated in the pathophysiology of EE, as described in U.S. Application Ser. No. 61/118,981, filed Dec. 1, 2008, which is incorporated by reference herein in its entirety.

The 1620 genes in the EE transcriptome are highly conserved. Their complex expression pattern delineates molecular features, cell composition, and cell activation in EE.

In one embodiment, the EE transcriptome was compared to transcriptomes in cell/tissues that had been treated with one or more compounds potentially involved with and/or efficacious against EE. By comparing the EE transcriptome to the transcriptome of, e.g., a simple in vitro or ex vivo model of a particular compound, one can assess the percentage of genes that are dysregulated in EE due to that particular compound.

For example, in ex vivo or in vitro models, a compound was used to stimulate an esophageal cell type. The genes that were dysregulated in this model, and hence exhibit an altered transcriptome, allowed one to determine the percentage of genes that were dysregulated in EE due to treatment with this compound. A transcriptome generated in esophageal epithelial cells that had been stimulated with IL-13 revealed that 20% of the genes of the EE transcriptome were potentially due to IL-13 stimulation of esophageal epithelial cells. These data permitted determination of the involvement of a compound in EE, e.g. that IL-13 was a key component in EE. These data permitted assessment of the percentage of gene(s) a compound would potentially block, e.g. that an inhibitor of the compound IL-13 would potentially reverse the expression of this same 20% of the EE transcriptome and predict the potential positive effect of the compound. These data permitted generation of a list of genes that would be expected to be down-regulated by a compound, and that thus could be used to assess the compound's efficacy on therapy and/or treatment compliance.

In one embodiment, evaluation of the EE transcriptome was used to determine efficacy of non-drug therapies. For example, having patients with EE follow a controlled diet, where some foodstuffs are limited or eliminated, normalized expression levels of many genes in the EE transcriptome, as shown in FIG. 6. Elimination diets that completely eliminate certain foodstuffs (e.g., wheat, soy, milk, peanuts, and/or seafood) and elemental diets that completely lack certain elements (e.g., liquid diets that contain only amino acids but no proteins to act as allergens) have been used with some success to treat children with EE. In one embodiment, the EE transcriptome is used to assess potential non-drug EE treatments by comparing the gene expression profile pre- and post-such treatment. For example, a child with EE may be put on an elimination diet for a defined period, and the gene expression profile compared before, during, and at the termination of the defined period to assess effect of the foodstuff that was eliminated from the child's diet during the period.

Some individuals with EE do not respond to treatment (FIG. 5). Even after they have received treatment (e.g., a particular drug, elimination diet, elemental diet, etc.), such non-responder individuals have an EE transcriptome that resembles untreated EE patients, i.e., genes that are up-regulated in EE and genes that are down-regulation in EE remain up-regulated and down-regulated, respectively, despite the individual having received a particular treatment for EE.

Analysis of the gene expression profile pre- and post-treatment allows a medical practitioner to determine whether a particular treatment method demonstrates efficacy, or whether an alternative form of treatment, or a different treatment regime (e.g., increased dosing) is warranted. In one embodiment, analysis of the EE transcriptome is used to assess whether a patient is responding to a particular treatment.

In one embodiment, analysis of the EE transcriptome is used to assess and/or monitor patient compliance. For example, a patient with EE may not respond to therapy because the patient is a non-responder, or may not respond to therapy because the patient is not complying with the complete dosage regimen and thus may have a subthreshold drug concentration.

In one embodiment, evaluation of the EE transcriptome was used to assess EE in the presence of another pathology that may confound the diagnosis of EE. While EE is commonly diagnosed using histological methods to assess the level of eosinophil infiltration into, and/or thickening of, esophageal tissue, the presence and extent of eosinophil infiltration can be affected by various factors. The esophagus is normally devoid of eosinophils. However eosinophils can infiltrate the esophagus in pathological condition such as parasitic infection, fungal infections, hypereosinophilic syndromes, inflammatory bowel disease, certain cancers, recurrent vomiting, gastroesophageal reflux disease (GERD), etc., in addition to EE, so eosinophil presence/concentration in the esophagus cannot definitively diagnose between, e.g., EE and GERD. These diseases need to be ruled out before EE can be diagnosed. Evaluation of the EE transcriptome to identify the genes specifically involved in EE, e.g., eotaxin-3, allows one to discriminate between these pathologies and rule in or rule out EE with enhanced definiteness.

The diagnosis of EE is often suspected whenever dysphagia for solid food occurs, although it is not one of the more common causes of dysphagia. Dysphagia is frequently evaluated with endoscopy (esophagogastroduodenoscopy, or EGD) to determine its cause. During EGD, a flexible viewing tube or endoscope is inserted through the mouth and into the esophagus, permitting the medical practitioner to see the inner esophageal mucosa and lumen. Certain abnormalities, such as narrowing of most of the esophagus, or a series of rings along the entire length of the esophagus, suggest EE. However, in many patients with EE, upon such visualization the esophagus appears normal or shows only minor abnormalities. Thus, an accurate diagnosis of EE using visual and/or histological methods depends on the presence of characteristics that may or may not be present. The accurate diagnosis of EE using histological evaluation of a tissue biopsy specimen depends on when the biopsy is obtained. For example, histological evaluation may differ in early-stage EE biopsy tissue compared to later-stage biopsy EE tissue. The accurate diagnosis of EE may be compromised if other pathologies are present. Evaluation of the EE transcriptome permitted a more accurate assessment, diagnosis, determination of course, etc., of EE. Evaluation of the EE transcriptome may be performed independent of, or concomitant with, other assessment methods such as, e.g., histological evaluation of a tissue biopsy specimen. Evaluation of the EE transcriptome may be performed, e.g., when eosinophil infiltration has not reached pre-determined numbers, in disease remission, in the absence of physical characteristics, or in the presence of one or more confounding pathologies.

In one embodiment, evaluation of the EE transcriptome is used to diagnose past, present, and/or future EE disease. When a patient with EE patient is treated successfully and, upon histological evaluation of a tissue biopsy specimen, presents no pathology, the pathologist, based upon the microscopic appearance, typically reports the patient as normal with no diagnosis abnormality. However, evaluation of the EE transcriptome reveals dysregulation of the 13 non-responsive genes despite the normal histological appearance of biopsy tissues. Thus, while eosinophil tissue infiltration is a marker of active EE, evaluation of the EE transcriptome provides information of EE history, e.g., it can assess presence and/or severity of prior pathology. Such assessment is useful because the dynamic and seasonal nature of EE is known.

In one embodiment, evaluation of the EE transcriptome is used to diagnose EE in the absence of overt disease, i.e., EE variability and/or inherency. In one embodiment, the expression level of the 13 non-responsive genes is used to diagnose EE in the absence of overt or active disease. In one embodiment, the 13 non-responsive genes allow diagnosis of chronic and relapsing forms of EE, and may provide an understanding of the pathophysiology of these forms. For example, evaluation of the EE transcriptome can identify sporadic, e.g. recurring or relapsing, forms of EE. As described above, histological assessment of a tissue biopsy specimen and extent of tissue eosinophil infiltration depends on when, during the course of EE, the assessment is performed. In contrast, a sporadic form of EE that is missed by these methods would, in fact, be captured by evaluating the EE transcriptome because the under-expression or over-expression exhibited by these genes is independent of active EE.

In one embodiment, evaluation of the EE transcriptome is used to assess familial components or contributions to EE by providing a transcriptome basis of comparison among genetic family members of the EE patient. There is evidence indicating a strong familial association or aggregation for EE. Approximately 10% of parents of EE patients have a history of esophageal strictures, and approximately 8% of these have EE as established by histological evaluation of a tissue biopsy specimen.

Among the approximately 300 first pediatric probands, e.g. individuals exhibiting EE, recruited into our research databank, 26 of them have at least one sibling or parent with EE (data not provided). Three adult brothers with dysphagia were reported to have EE (Patel and Falchuk). One widely used measure of familial aggregation is the sibling recurrence risk ratio, termed λS, that compares the risk of sibling disease recurrence versus the risk, or disease prevalence, in the general population. A value for λS>1 indicates an increased risk of EE development among siblings of the proband, compared to the general population. The prevalence of EE in the general population is approximately 5/10,000. Based on this prevalence, the estimated sibling recurrence risk ratio, λS, for EE is approximately 80. Compared with common allergic disorders, such as atopy or asthma where λS is estimated at approximately 2, the considerably high sibling recurrence risk ratio in EE indicated that genetics was likely to have a relatively large role.

In one embodiment, evaluation of the EE transcriptome is used to identify candidate genes responsible for a familiar association. The gene for eotaxin-3 gene was one candidate gene. A single nucleotide polymorphism (SNP), +2496 T>G, rs2302009) in the gene for eotaxin-3 showed association with EE by both population-based case-control comparison and family-based transmission disequilibrium testing. Thus, the evaluation of the EE transcriptome among genetic family members, some of who exhibited symptoms of EE, may provide early EE diagnosis in other family members who did not exhibit symptoms. Such information facilitates determination of hereditary factors for EE.

In one embodiment, a diagnostic assay for eosinophilic esophagitis includes an ELISA (enzyme linked immunosorbent assay) or other clinically applicable immunoassay. In another embodiment, a diagnostic assay for eosinophilic esophagitis includes a test strip containing an anti-eotaxin-3 binding substance such as an antibody to which eotaxin-3 or eotaxin-3 like protein or peptide in a patient's biological sample (e.g. blood, sputum, feces, tissue fluid, cerebrospinal fluid, etc.) would bind. The test strip may include a chromogenic, fluorogenic, or luminescent substrate, detection reagents, etc., as known to one skilled in the art. The anti-eotaxin-3 antibody may be a rodent or other animal antieotaxin-3 antibody. The assay would include at least one suitable reagent, such as an enzyme (e.g. an oxidoreductase, transferase, hydrolase, lyase, isomerase, or ligase), in one embodiment horseradish peroxidase, o-toluidine, or colloidal gold, whereby the reagent reacts with an antigen/antibody complex on the test strip. A chromogen or other detectable indicator of binding or lack of binding, depending upon the assay format (e.g. competitive, non-competitive, sandwich, etc.) indicates binding of the anti-eotaxin-3 antibody to eotaxin-3 present in a supranormal level for a qualitative test, and may indicate the degree of binding for a quantitative or semi-quantitative test. Binding typically is indicated or visually detected via the presence or absence of color, fluorescence, luminescence, etc. Such test kit components and configurations are well known to one skilled in the art and are within the scope of the invention. An example of certain suitable substrates and a suitable reagent may include, respectively, dimethyl or diethyl analogues of p-phenylenediamine with 4-chloro-1-naphthol or 3-methyl-2-benzothiazoline hydrazone with 4-chloro-1-naphthol and horseradish peroxidase. Other exemplary substrates used with horseradish peroxidase include 3,3′,5,5′-tetramethylbenzidine, 2,2′-azinobis[3-ethylbenzothiazoline-6-sulfonic acid]-diammonium salt, o-phenylenediamine dihydrochloride, and QuantaBlu.

The anti-eotaxin-3 antibody may be a monoclonal or polyclonal antibody. Methods of producing monoclonal and polyclonal antibodies are known to one skilled in the art. Anti-eotaxin-3 antibodies may be generated as disclosed in U.S. Pat. No. 6,780,973, previously expressly incorporated by reference herein in its entirety. Also, a commercially available anti-eotaxin-3 antibody may be used. As indicated above, eotaxin-3 selectively signals through the CCR3 receptor expressed on activated eosinophils or on other cells such as mast cells. As such, eosinophilic esophagitis may be mitigated by altering an eotaxin-3 binding and/or signaling mechanism, and/or CCR3 structure, function, and/or internalization. One such example is a method to provide an inhibitor to eotaxin-3 and/or CCR3 in an eosinophil or a mast cell under conditions sufficient to inhibit eotaxin-3 binding to the receptor. For example, the inhibitor may be provided to the esophageal tissue or to the blood stream in an amount sufficient to inhibit eotaxin-3 binding to the eotaxin-3 receptor. The inhibitor may be a small molecule inhibitor and/or a CCR3 antagonist. Exemplary CCR3 antagonists may include a humanized or human antieotaxin-3 antibody, MIG, I-TAO, IP-10 (U.S. patent application Ser. No. 10/752,659, titled “Cytokine Inhibition of Eosinophils,” filed on Jan. 1, 2004; Zimmermann et al., J. Allergy Clin. Immunol., (2003) 3, 227), vMIP-II (Kleidel et al., Science, (1997) 277, 1656), met-RANTES (Elsner et al., Eur. J. Immunol., (1997) 27, 2892), carboxamide derivatives (Naya et al., Bioorg. Med. Chem. Lett., (2001) 11, 1219), 2-(Benzothiazolylthio)acetamide derivatives (Naya et al., Chem. Pharm. Bull., (2003) 51, 697; Saeki et al., Biochem. Biophys. Res. Comm., (2001) 281, 779), piperidine derivatives including indolinopiperidines or benzylpiperidines (Wacker et al., Bioorg. Med. Chem. Leit., (2002)12, 1785; Varnes et al., Bioorg. Med. Chem. Lett., (2004) 14, 1645), or such other nonpeptides as UCB35625 and derivatives thereof (Sabroe et al., J. Biol. Chem., (2000) 275, 25985), and SK&F-_L-45523 and derivatives thereof (White et al., J. Biol. Chem., (2000) 275, 36626). Certain of the above antagonists, e.g., UCB35625, may also be considered small molecule inhibitors (Sabroe et al., J. Biol. Chem., (2000) 275, 25985). Each of the references cited is expressly incorporated by reference herein in its entirety.

The inhibitor need not completely inhibit binding, signal transduction, and/or function or cause receptor internalization. As used herein, an inhibitor may cause any reduction in one or more of these properties compared to a normal level. An eotaxin-3 and/or CCR3 inhibitor may also specifically inhibit transcription and/or translation of eotaxin-3, and/or CCR3 such as by utilizing antisense oligonucleotides and transcription factor inhibitors. An inhibitor may include a glucocorticoid that can work by inhibiting eotaxin-3 promoter-driven reporter gene activity and accelerating the decay of eotaxin-3 mRNA (Zimmermann et al., J. Allergy Clin. Immunol., (2003) 3, 227). An inhibitor may also induce CCR3 internalization (Zimmermann et al., J. Biol. Chem., (1999) 274, 12611). Each of the references cited is expressly incorporated by reference herein in its entirety. An inhibitor may be administered directly or with a pharmaceutically acceptable diluent, carrier, or excipient, in unit dosage form. Conventional pharmaceutical practice may be employed to provide suitable formulations or compositions to administer the inhibitor to patients with, or presymptomatic for, eosinophilic esophagitis. Any appropriate route of administration may be employed, for example, parenteral, intravenous, subcutaneous, intramuscular, intracranial, intraorbital, ophthalmic, intraventricular, intracapsular, intraspinal, intracistemal, intraperitoneal, intranasal, aerosol, or oral administration. Therapeutic formulations may be in the form of solids, liquid solutions, or suspensions; for oral administration, formulations may be in the form of tablets (chewable, dissolvable, etc.), capsules (hard or soft gel), pills, syrups, elixirs, emulsions, etc.; and for intranasal formulations, in the form of powders, nasal drops, or aerosols. In one embodiment, a CCR3 antagonist is administered parenterally and/or orally. Enteral formulations may contain thixotropic agents, flavoring agents, and other ingredients for enhancing organoleptic qualities.

Methods known in the art for making formulations are found in, for example, “Remington's Pharmaceutical Sciences.” Formulations for parenteral administration may, for example, contain excipients, including but not limited to pharmaceutically acceptable buffers, emulsifiers, surfactants, and electrolytes such as sodium chloride, as well as sterile water, or saline, polyalkylene glycols such as polyethylene glycol, oils of vegetable origin, or hydrogenated napthalenes. Biocompatible, biodegradable lactide polymer, lactide/glycolide copolymer, or polyoxyethylene-polyoxypropylene copolymers may be used to control the release of the compounds. Formulations for inhalation may also contain excipients, for example, lactose, or may be aqueous solutions containing, for example, polyoxyethylene-9-lauryl ether, glycocholate and deoxycholate, or may be oily solutions for administration in the form of nasal drops, or as a gel.

Applicants incorporate by reference the material contained in the accompanying computer readable Sequence Listing identified as SEQUENCE_LISTING_ST25.txt, having a file creation date of Jun. 24, 2009 3:30 P.M. and a file size of 6.98 MB.

Other variations or embodiments of the invention will also be apparent to one of ordinary skill in the art from the above figures and descriptions. Thus, the forgoing embodiments are not to be construed as limiting the scope of this invention.

Claims

1. A method to evaluate an individual's propensity for eosinophilic esophagitis (ee), the method comprising

determining an expression profile of at least one gene selected from the group consisting of SEQ ID NOS. 1-1620 in an esophagus of an individual,

comparing the expression profile of the at least one gene of the individual with an expression profile from an individual without EE,

evaluating the individual's propensity for EE by determining if the at least one gene is either over-expressed ≧1.5 times or is under-expressed ≧1.5 times compared to the same gene in the expression profile from the individual without EE, and

ranking the individual's propensity for EE based on at least one of (a) the extent that over-expression or under-expression exceeds 1.5, (b) the identify of the gene over-expressed or under-expressed, or (c) the number of genes that are over-expressed or under-expressed, where the individual has a higher propensity for EE when (a) is farther from 1.5, (b) is selected from the group consisting of SEQ ID NOS. 1-42, and (c) is farther from 1.

2. The method of claim 1 wherein (b) is SEQ ID NO. 1.

3. The method of claim 1 wherein the individual lacks at least one of clinical and physical symptoms of EE.

4. A method to evaluate a compound's contribution to the pathophysiology of eosinophilic esophagitis (EE), the method comprising

exposing at least one cell to the compound,

comparing an expression profile of at least one gene selected from the group consisting of SEQ ID NOS. 1-1620 in the at least one cell to an expression profile of at least one gene selected from the group consisting of SEQ ID NOS. 1-1620 in a cell of an individual without EE,

evaluating the contribution of the compound to the pathophysiology of EE by determining if the at least one gene in the cell is either over-expressed ≧1.5 times or is under-expressed ≧1.5 times compared to the same gene in the expression profile of the individual without EE, and

ranking the compound's contribution to the pathophysiology of EE based on at least one of (a) the extent that over-expression or under-expression exceeds 1.5, (b) the identify of the gene over-expressed or under-expressed, or (c) the number of genes that are over-expressed or under-expressed, where the compound contributes more to the pathophysiology of EE when (a) is farther from 1.5, (b) is selected from the group consisting of SEQ ID NOS. 1-42, and (c) is farther from 1.

5. The method of claim 4 wherein the cell is an esophageal cell.

6. A method to evaluate whether an individual had prior eosinophilic esophagitis (EE), the method comprising

determining an expression profile of at least one gene selected from the group consisting of SEQ ID NOS. 6, 35, 43, 61, 129, 1358, 1441, 1515, 1538, 1584, 1615, 1618, and 1620 in an esophagus of an individual,

comparing the expression profile of the at least one gene of the individual with an expression profile from an individual without EE,

evaluating whether the individual had prior EE by determining if the at least one gene is either over-expressed ≧1.5 times or is under-expressed ≧1.5 times compared to the same gene in the expression profile from the individual without EE, and

ranking the likelihood that the individual had prior EE based on at least one of (a) the extent that over-expression or under-expression exceeds 1.5, or (b) the number of genes that are over-expressed or under-expressed, where the individual is more likely to have had EE when (a) is farther from 1.5, and (b) is farther from 1.

7. The method of claim 6 where the individual does not have active EE.